1,213 results on '"Liu, Kathleen D."'
Search Results
2. Incidence of acute kidney injury and attributive mortality in acute respiratory distress syndrome randomized trials
- Author
-
Antonucci, Edoardo, Garcia, Bruno, Chen, David, Matthay, Michael A., Liu, Kathleen D., and Legrand, Matthieu
- Published
- 2024
- Full Text
- View/download PDF
3. Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis.
- Author
-
Rosenberger, Carrie M, Wick, Katherine D, Zhuo, Hanjing, Wu, Nelson, Chen, Yue, Kapadia, Sharookh B, Guimaraes, Alessander, Chang, Diana, Choy, David F, Chen, Hubert, Peck, Melicent, Sullivan, Kathryn M, Ke, Serena, Jauregui, Alejandra, Leligdowicz, Aleksandra, Sinha, Pratik, Gomez, Antonio D, Kangelaris, Kirsten N, Delucchi, Kevin, Liu, Kathleen D, Calfee, Carolyn S, Matthay, Michael A, and Hendrickson, Carolyn M
- Subjects
Humans ,Sepsis ,Critical Illness ,Angiopoietin-2 ,Prognosis ,Pandemics ,Respiratory Distress Syndrome ,COVID-19 ,Clinical Research ,Infectious Diseases ,Hematology ,Lung ,Acute Respiratory Distress Syndrome ,Rare Diseases ,4.1 Discovery and preclinical testing of markers and technologies ,2.1 Biological and endogenous factors ,Detection ,screening and diagnosis ,Aetiology ,Inflammatory and immune system ,Good Health and Well Being ,Medical and Health Sciences ,Emergency & Critical Care Medicine - Abstract
Angiopoietin-2 (Ang-2) is associated with vascular endothelial injury and permeability in the acute respiratory distress syndrome (ARDS) and sepsis. Elevated circulating Ang-2 levels may identify critically ill patients with distinct pathobiology amenable to targeted therapy. We hypothesized that plasma Ang-2 measured shortly after hospitalization among patients with sepsis would be associated with the development of ARDS and poor clinical outcomes. To test this hypothesis, we measured plasma Ang-2 in a cohort of 757 patients with sepsis, including 267 with ARDS, enrolled in the emergency department or early in their ICU course before the COVID-19 pandemic. Multivariable models were used to test the association of Ang-2 with the development of ARDS and 30-day morality. We found that early plasma Ang-2 in sepsis was associated with higher baseline severity of illness, the development of ARDS, and mortality risk. The association between Ang-2 and mortality was strongest among patients with ARDS and sepsis as compared to those with sepsis alone (OR 1.81 vs. 1.52 per log Ang-2 increase). These findings might inform models testing patient risk prediction and strengthen the evidence for Ang-2 as an appealing biomarker for patient selection for novel therapeutic agents to target vascular injury in sepsis and ARDS.
- Published
- 2023
4. Longitudinal biomarkers and kidney disease progression after acute kidney injury.
- Author
-
Wen, Yumeng, Xu, Leyuan, Melchinger, Isabel, Thiessen-Philbrook, Heather, Moledina, Dennis G, Coca, Steven G, Hsu, Chi-Yuan, Go, Alan S, Liu, Kathleen D, Siew, Edward D, Ikizler, T Alp, Chinchilli, Vernon M, Kaufman, James S, Kimmel, Paul L, Himmelfarb, Jonathan, Cantley, Lloyd G, Parikh, Chirag R, and ASSESS-AKI Consortium
- Subjects
ASSESS-AKI Consortium ,Kidney ,Animals ,Mice ,Disease Progression ,Inflammation ,Prospective Studies ,Renal Insufficiency ,Chronic ,Acute Kidney Injury ,Biomarkers ,Chronic kidney disease ,Diagnostics ,Epidemiology ,Nephrology ,Prevention ,Kidney Disease ,Clinical Research ,Aetiology ,2.1 Biological and endogenous factors ,Renal and urogenital ,Good Health and Well Being - Abstract
BACKGROUNDLongitudinal investigations of murine acute kidney injury (AKI) suggest that injury and inflammation may persist long after the initial insult. However, the evolution of these processes and their prognostic values are unknown in patients with AKI.METHODSIn a prospective cohort of 656 participants hospitalized with AKI, we measured 7 urine and 2 plasma biomarkers of kidney injury, inflammation, and tubular health at multiple time points from the diagnosis to 12 months after AKI. We used linear mixed-effect models to estimate biomarker changes over time, and we used Cox proportional hazard regressions to determine their associations with a composite outcome of chronic kidney disease (CKD) incidence and progression. We compared the gene expression kinetics of biomarkers in murine models of repair and atrophy after ischemic reperfusion injury (IRI).RESULTSAfter 4.3 years, 106 and 52 participants developed incident CKD and CKD progression, respectively. Each SD increase in the change of urine KIM-1, MCP-1, and plasma TNFR1 from baseline to 12 months was associated with 2- to 3-fold increased risk for CKD, while the increase in urine uromodulin was associated with 40% reduced risk for CKD. The trajectories of these biological processes were associated with progression to kidney atrophy in mice after IRI.CONCLUSIONSustained tissue injury and inflammation, and slower restoration of tubular health, are associated with higher risk of kidney disease progression. Further investigation into these ongoing biological processes may help researchers understand and prevent the AKI-to-CKD transition.FUNDINGNIH and NIDDK (grants U01DK082223, U01DK082185, U01DK082192, U01DK082183, R01DK098233, R01DK101507, R01DK114014, K23DK100468, R03DK111881, K01DK120783, and R01DK093771).
- Published
- 2023
5. Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
- Author
-
Consortium, The I-SPY COVID, Files, D Clark, Aggarwal, Neil, Albertson, Timothy, Auld, Sara, Beitler, Jeremy R, Berger, Paul, Burnham, Ellen L, Calfee, Carolyn S, Cobb, Nathan, Crippa, Alessio, Discacciati, Andrea, Eklund, Martin, Esserman, Laura, Friedman, Eliot, Gandotra, Sheetal, Khan, Kashif, Koff, Jonathan, Kumar, Santhi, Liu, Kathleen D, Martin, Thomas R, Matthay, Michael A, Meyer, Nuala J, Obermiller, Timothy, Robinson, Philip, Russell, Derek, Thomas, Karl, Wong, Fum, Wunderink, Richard G, Wurfel, Mark M, Yen, Albert, Youssef, Fady A, Darmanian, Anita, Dzierba, Amy L, Garcia, Ivan, Gosek, Katarzyna, Madahar, Purnema, Mittel, Aaron M, Muir, Justin, Rosen, Amanda, Schicchi, John, Serra, Alexis L, Wahab, Romina, Gibbs, Kevin W, Landreth, Leigha, LaRose, Mary, Parks, Lisa, Wynn, Adina, Ittner, Caroline AG, Mangalmurti, Nilman S, Reilly, John P, Harris, Donna, Methukupally, Abhishek, Patel, Siddharth, Boerger, Lindsie, Kazianis, John, Higgins, Carrie, McKeehan, Jeff, Daniel, Brian, Fields, Scott, Hurst-Hopf, James, Jauregui, Alejandra, Swigart, Lamorna Brown, Blevins, Daniel, Nguyen, Catherine, Suarez, Alexis, Tanios, Maged A, Sarafian, Farjad, Shah, Usman, Adelman, Max, Creel-Bulos, Christina, Detelich, Joshua, Harris, Gavin, Nugent, Katherine, Spainhour, Christina, Yang, Philip, Haczku, Angela, Hardy, Erin, Harper, Richart, Morrissey, Brian, Sandrock, Christian, Budinger, GR Scott, Donnelly, Helen K, Singer, Benjamin D, Moskowitz, Ari, Coleman, Melissa, Levitt, Joseph, Lu, Ruixiao, Henderson, Paul, Asare, Adam, Dunn, Imogene, and Barragan, Alejandro Botello
- Subjects
Health Services ,Clinical Trials and Supportive Activities ,Clinical Research ,Good Health and Well Being ,I-SPY COVID Consortium ,Acute lung injury ,Clinical trial ,Respiratory insufficiency ,SARS-CoV-2 - Abstract
BackgroundAn urgent need exists to rapidly screen potential therapeutics for severe COVID-19 or other emerging pathogens associated with high morbidity and mortality.MethodsUsing an adaptive platform design created to rapidly evaluate investigational agents, hospitalised patients with severe COVID-19 requiring ≥6 L/min oxygen were randomised to either a backbone regimen of dexamethasone and remdesivir alone (controls) or backbone plus one open-label investigational agent. Patients were enrolled to the arms described between July 30, 2020 and June 11, 2021 in 20 medical centres in the United States. The platform contained up to four potentially available investigational agents and controls available for randomisation during a single time-period. The two primary endpoints were time-to-recovery (
- Published
- 2023
6. Initiation of continuous renal replacement therapy versus intermittent hemodialysis in critically ill patients with severe acute kidney injury: a secondary analysis of STARRT-AKI trial
- Author
-
Wald, Ron, Gaudry, Stephane, da Costa, Bruno R., Adhikari, Neill K. J., Bellomo, Rinaldo, Du, Bin, Gallagher, Martin P., Hoste, Eric A., Lamontagne, François, Joannidis, Michael, Liu, Kathleen D., McAuley, Daniel F., McGuinness, Shay P., Nichol, Alistair D., Ostermann, Marlies, Palevsky, Paul M., Qiu, Haibo, Pettilä, Ville, Schneider, Antoine G., Smith, Orla M., Vaara, Suvi T., Weir, Matthew, Dreyfuss, Didier, and Bagshaw, Sean M.
- Published
- 2023
- Full Text
- View/download PDF
7. Hospitalized Patients With COVID-19 Have Higher Plasma Aldosterone-Renin Ratio and Lower ACE Activity Than Controls
- Author
-
Parikh, Nisha I, Arowolo, Folagbayi, Durstenfeld, Matthew S, Nah, Gregory, Njoroge, Joyce, Vittinghoff, Eric, Long, Carlin S, Ganz, Peter, Pearce, David, Hsue, Priscilla, Wu, Alan HS, Hajizadeh, Negin, Liu, Kathleen D, and Lynch, Kara L
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Cardiovascular ,Lung ,Good Health and Well Being ,COVID-19 ,renin-aldosterone ratio ,hospitalization ,severity ,renin-angiotensin aldosterone system ,obesity ,ACE-2 ,biomarkers ,Cardiovascular medicine and haematology - Abstract
ContextSARS-CoV-2 infects cells via the angiotensin converting enzyme 2 (ACE2) receptor, whose downstream effects "counterbalance" the classical renin angiotensin aldosterone system (RAAS).ObjectiveWe aimed to determine to what extent circulating RAAS biomarker levels differ in persons with and without COVID-19 throughout the disease course.MethodsWe measured classical (renin, aldosterone, aldosterone/renin ratio [ARR], Ang2, ACE activity) and nonclassical (ACE2, Ang1,7) RAAS biomarkers in hospitalized COVID-19 patients vs SARS-CoV-2 negative controls. We compared biomarker levels in cases with contemporaneous samples from control patients with upper respiratory symptoms and a negative SARS-CoV-2 PCR test. To assess RAAS biomarker changes during the course of COVID-19 hospitalization, we studied cases at 2 different times points ∼ 12 days apart. We employed age- and sex-adjusted generalized linear models and paired/unpaired t tests.ResultsMean age was 51 years for both cases (31% women) and controls (50% women). ARR was higher in the first sample among hospitalized COVID-19 patients vs controls (P = 0.02). ACE activity was lower among cases at their first sample vs controls (P =
- Published
- 2022
8. Inflammatory and coagulant responses after acute respiratory failure in children of different body habitus
- Author
-
Ward, Shan L., Flori, Heidi R., Dahmer, Mary K., Weeks, Heidi M., Sapru, Anil, Quasney, Michael W., Curley, Martha A. Q., Liu, Kathleen D., and Matthay, Michael A.
- Published
- 2023
- Full Text
- View/download PDF
9. Association Between Kidney Dysfunction Types and Mortality Among Hospitalized Patients with Cirrhosis
- Author
-
Cullaro, Giuseppe, Rubin, Jessica B, Fortune, Brett E, Crawford, Carl V, Verna, Elizabeth C, Hsu, Chi-yuan, Liu, Kathleen D, Brown, Robert S, Lai, Jennifer C, and Rosenblatt, Russell
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Kidney Disease ,Clinical Research ,Renal and urogenital ,Good Health and Well Being ,Acute Kidney Injury ,Hospital Mortality ,Humans ,Kidney ,Liver Cirrhosis ,Renal Insufficiency ,Chronic ,Risk Factors ,Acute kidney injury ,Chronic kidney disease ,Cirrhosis ,Hospitalizations ,Mortality ,National inpatient sample ,Gastroenterology & Hepatology ,Clinical sciences - Abstract
Background and aimsKidney dysfunction is associated with increased mortality among patients with cirrhosis. We investigated whether kidney dysfunction types [e.g., acute kidney injury (AKI), chronic kidney disease (CKD), and AKI on CKD] were differentially associated with inpatient mortality.MethodsWe utilized the nationwide inpatient sample, a nationally representative database, from 2007 to 2014. We included all hospitalizations with previously validated codes for cirrhosis or associated decompensated cirrhosis diagnoses. We defined kidney dysfunction types also from previously validated codes, and we grouped hospitalizations into the following diagnoses: normal, AKI, CKD, and AKI on CKD. Our primary outcome was inpatient mortality.ResultsThere were 1,293,779 hospitalizations with cirrhosis sampled in this study. Of these hospitalizations, 849,193 (66%) had normal kidney function, 176,418 (14%) had AKI, 157,600 (12%) had CKD, and 110,568 (9%) had AKI on CKD. We found that the proportion of hospitalizations with AKI, CKD, and AKI on CKD increased significantly throughout the study period (p
- Published
- 2022
10. Considerations in Controlling for Urine Concentration for Biomarkers of Kidney Disease Progression After Acute Kidney Injury
- Author
-
Wen, Yumeng, Thiessen-Philbrook, Heather, Moledina, Dennis G, Kaufman, James S, Reeves, W Brian, Ghahramani, Nasrollah, Ikizler, T Alp, Go, Alan S, Liu, Kathleen D, Siew, Eddie D, Himmelfarb, Jonathan, Kimmel, Paul L, Hsu, Chi-yuan, and Parikh, Chirag R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Kidney Disease ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Renal and urogenital ,Good Health and Well Being ,acute kidney injury ,biomarker ,chronic kidney disease ,urine concentration ,urine creatinine ,urine osmolarity ,Biomedical and clinical sciences ,Health sciences - Abstract
IntroductionBiomarkers of acute kidney injury (AKI) are often indexed to urine creatinine (UCr) or urine osmolarity (UOsm) to control for urine concentration. We evaluated how these approaches affect the biomarker-outcome association in patients with AKI.MethodsThe Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury Study was a cohort of hospitalized patients with and without AKI between 2009 and 2015. Using Cox proportional hazards regression, we assessed the associations and predictions (C-statistics) of urine biomarkers with a composite outcome of incident chronic kidney disease (CKD) and CKD progression. We used 4 approaches to account for urine concentration: indexing and adjusting for UCr and UOsm.ResultsAmong 1538 participants, 769 (50%) had AKI and 300 (19.5%) developed composite CKD outcome at median follow-up of 4.7 years. UCr and UOsm during hospitalization were inversely associated with the composite CKD outcome. The associations and predictions with CKD were significantly strengthened after indexing or adjusting for UCr or UOsm for urine kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), and monocyte chemoattractant protein-1 (MCP-1) in patients with AKI. There was no significant improvement with indexing or adjusting UCr or UOsm for albumin, neutrophil gelatinase-associated lipocalin (NGAL), and chitinase 3-like 1 (YKL-40). Uromodulin's (UMOD) inverse association with the outcome was significantly blunted after indexing but not adjusting for UCr or UOsm.ConclusionUCr and UOsm during hospitalization are inversely associated with development and progression of CKD. Indexing or adjusting for UCr or UOsm strengthened associations and improved predictions for CKD for only some biomarkers. Incorporating urinary concentration should be individualized for each biomarker in research and clinical applications.
- Published
- 2022
11. I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations
- Author
-
Files, Daniel Clark, Matthay, Michael A, Calfee, Carolyn S, Aggarwal, Neil R, Asare, Adam L, Beitler, Jeremy R, Berger, Paul A, Burnham, Ellen L, Cimino, George, Coleman, Melissa H, Crippa, Alessio, Discacciati, Andrea, Gandotra, Sheetal, Gibbs, Kevin W, Henderson, Paul T, Ittner, Caroline AG, Jauregui, Alejandra, Khan, Kashif T, Koff, Jonathan L, Lang, Julie, LaRose, Mary, Levitt, Joe, Lu, Ruixiao, McKeehan, Jeffrey D, Meyer, Nuala J, Russell, Derek W, Thomas, Karl W, Eklund, Martin, Esserman, Laura J, Liu, Kathleen D, Mittel, Aaron M, Yen, Albert F, Suarez, Alexis E, Serra, Alexis L, Amin, Alpesh N, Rosen, Amanda, Dzierba, Amy L, Haczku, Angela, Barker, Anna D, Weisman, Ariel R, Daniel, Brian M, Morrissey, Brian M, Jones, Chayse, Creel-Bulos, Christina, Angelucci, Christina M, Files, Daniel C, Ng, Diana, Youssef, Fady A, Chaparro-Rojas, Fredy, Harris, Gavin H, Barot, Harsh V, Su, Heny, Garcia, Ivan, Sutter, Jacqueline B, Dodin, Jamal, Lee, Jerry S, Kazianis, John, Reilly, John P, Detelich, Joshua F, Lang, Julie E, Muir, Justin, Gosek, Katarzyna, Nugent, Katherine L, Yee, Kimberly, Rodrigues, Laura G, Macias, Laura R, Orr, Lindsey A, Boerger, Lindsie L, Rosario-Remigio, Lissette, Kufa, Lucia, Huerta, Luis E, Tanios, Maged, Reyes, Maria B, Adelman, Max W, Juarez, Maya M, Jung, Michelle, Meyers, Michelle, Sternlieb, Mitchell P, Cobb, Nathan K, and Aggarwal, Neil
- Subjects
Clinical Research ,Clinical Trials and Supportive Activities ,Good Health and Well Being ,Bayes Theorem ,COVID-19 ,Humans ,Pandemics ,Respiratory Distress Syndrome ,Respiratory Insufficiency ,SARS-CoV-2 ,Treatment Outcome ,ISPY COVID Adaptive Platform Trial Network ,undefined ,adult intensive & critical care ,clinical trials ,Clinical Sciences ,Public Health and Health Services ,Other Medical and Health Sciences - Abstract
IntroductionThe COVID-19 pandemic brought an urgent need to discover novel effective therapeutics for patients hospitalised with severe COVID-19. The Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis (ISPY COVID-19 trial) was designed and implemented in early 2020 to evaluate investigational agents rapidly and simultaneously on a phase 2 adaptive platform. This manuscript outlines the design, rationale, implementation and challenges of the ISPY COVID-19 trial during the first phase of trial activity from April 2020 until December 2021.Methods and analysisThe ISPY COVID-19 Trial is a multicentre open-label phase 2 platform trial in the USA designed to evaluate therapeutics that may have a large effect on improving outcomes from severe COVID-19. The ISPY COVID-19 Trial network includes academic and community hospitals with significant geographical diversity across the country. Enrolled patients are randomised to receive one of up to four investigational agents or a control and are evaluated for a family of two primary outcomes-time to recovery and mortality. The statistical design uses a Bayesian model with 'stopping' and 'graduation' criteria designed to efficiently discard ineffective therapies and graduate promising agents for definitive efficacy trials. Each investigational agent arm enrols to a maximum of 125 patients per arm and is compared with concurrent controls. As of December 2021, 11 investigational agent arms had been activated, and 8 arms were complete. Enrolment and adaptation of the trial design are ongoing.Ethics and disseminationISPY COVID-19 operates under a central institutional review board via Wake Forest School of Medicine IRB00066805. Data generated from this trial will be reported in peer-reviewed medical journals.Trial registration numberNCT04488081.
- Published
- 2022
12. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis
- Author
-
Maddali, Manoj V, Churpek, Matthew, Pham, Tai, Rezoagli, Emanuele, Zhuo, Hanjing, Zhao, Wendi, He, June, Delucchi, Kevin L, Wang, Chunxue, Wickersham, Nancy, McNeil, J Brennan, Jauregui, Alejandra, Ke, Serena, Vessel, Kathryn, Gomez, Antonio, Hendrickson, Carolyn M, Kangelaris, Kirsten N, Sarma, Aartik, Leligdowicz, Aleksandra, Liu, Kathleen D, Matthay, Michael A, Ware, Lorraine B, Laffey, John G, Bellani, Giacomo, Calfee, Carolyn S, Sinha, Pratik, Rios, Fernando, Van Haren, Frank, Sottiaux, T, Lora, Fredy S, Azevedo, Luciano C, Depuydt, P, Fan, Eddy, Bugedo, Guillermo, Qiu, Haibo, Gonzalez, Marcos, Silesky, Juan, Cerny, Vladimir, Nielsen, Jonas, Jibaja, Manuel, Pham, Tài, Wrigge, Hermann, Matamis, Dimitrios, Ranero, Jorge Luis, Hashemian, SM, Amin, Pravin, Clarkson, Kevin, Kurahashi, Kiyoyasu, Villagomez, Asisclo, Zeggwagh, Amine Ali, Heunks, Leo M, Laake, Jon Henrik, Palo, Jose Emmanuel, do Vale Fernandes, Antero, Sandesc, Dorel, Arabi, Yaasen, Bumbasierevic, Vesna, Nin, Nicolas, Lorente, Jose A, Larsson, Anders, Piquilloud, Lise, Abroug, Fekri, McAuley, Daniel F, McNamee, Lia, Hurtado, Javier, Bajwa, Ed, Démpaire, Gabriel, Francois, Guy M, Sula, Hektor, Nunci, Lordian, Cani, Alma, Zazu, Alan, Dellera, Christian, Insaurralde, Carolina S, Alejandro, Risso V, Daldin, Julio, Vinzio, Mauricio, Fernandez, Ruben O, Cardonnet, Luis P, Bettini, Lisandro R, Bisso, Mariano Carboni, Osman, Emilio M, Setten, Mariano G, Lovazzano, Pablo, Alvarez, Javier, Villar, Veronica, Milstein, Cesar, Pozo, Norberto C, Grubissich, Nicolas, Plotnikow, Gustavo A, Vasquez, Daniela N, Ilutovich, Santiago, Tiribelli, Norberto, Chena, Ariel, Pellegrini, Carlos A, Saenz, María G, Estenssoro, Elisa, Brizuela, Matias, and Gianinetto, Hernan
- Subjects
Lung ,Clinical Research ,Acute Respiratory Distress Syndrome ,Rare Diseases ,Respiratory ,Good Health and Well Being ,Acute Lung Injury ,Humans ,Machine Learning ,Positive-Pressure Respiration ,Respiratory Distress Syndrome ,Retrospective Studies ,LUNG SAFE Investigators and the ESICM Trials Group ,Clinical Sciences ,Public Health and Health Services ,Other Medical and Health Sciences - Abstract
BackgroundTwo acute respiratory distress syndrome (ARDS) subphenotypes (hyperinflammatory and hypoinflammatory) with distinct clinical and biological features and differential treatment responses have been identified using latent class analysis (LCA) in seven individual cohorts. To facilitate bedside identification of subphenotypes, clinical classifier models using readily available clinical variables have been described in four randomised controlled trials. We aimed to assess the performance of these models in observational cohorts of ARDS.MethodsIn this observational, multicohort, retrospective study, we validated two machine-learning clinical classifier models for assigning ARDS subphenotypes in two observational cohorts of patients with ARDS: Early Assessment of Renal and Lung Injury (EARLI; n=335) and Validating Acute Lung Injury Markers for Diagnosis (VALID; n=452), with LCA-derived subphenotypes as the gold standard. The primary model comprised only vital signs and laboratory variables, and the secondary model comprised all predictors in the primary model, with the addition of ventilatory variables and demographics. Model performance was assessed by calculating the area under the receiver operating characteristic curve (AUC) and calibration plots, and assigning subphenotypes using a probability cutoff value of 0·5 to determine sensitivity, specificity, and accuracy of the assignments. We also assessed the performance of the primary model in EARLI using data automatically extracted from an electronic health record (EHR; EHR-derived EARLI cohort). In Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE; n=2813), a multinational, observational ARDS cohort, we applied a custom classifier model (with fewer variables than the primary model) to determine the prognostic value of the subphenotypes and tested their interaction with the positive end-expiratory pressure (PEEP) strategy, with 90-day mortality as the dependent variable.FindingsThe primary clinical classifier model had an area under receiver operating characteristic curve (AUC) of 0·92 (95% CI 0·90-0·95) in EARLI and 0·88 (0·84-0·91) in VALID. Performance of the primary model was similar when using exclusively EHR-derived predictors compared with manually curated predictors (AUC=0·88 [95% CI 0·81-0·94] vs 0·92 [0·88-0·97]). In LUNG SAFE, 90-day mortality was higher in patients assigned the hyperinflammatory subphenotype than in those with the hypoinflammatory phenotype (414 [57%] of 725 vs 694 [33%] of 2088; p
- Published
- 2022
13. Kidney Dysfunction After Acute Heart Failure: Is Acute Kidney Disease the New Acute Kidney Injury?
- Author
-
Kwong, Y Diana, Liu, Kathleen D, and Hsu, Raymond K
- Subjects
Biomedical and Clinical Sciences ,Health Sciences ,Biomedical and clinical sciences ,Health sciences - Published
- 2022
14. Elevated Hemoglobin A1c and the Risk of Developing ARDS in Two Cohort Studies
- Author
-
Bogart, Avery M., Lopez, Christine R., Obeidalla, Sarah N., Wang, Chunxue, Willmore, Andrew, Jauregui, Alejandra, Kangelaris, Kirsten N., Hendrickson, Carolyn, Gomez, Antonio, Liu, Kathleen D., Matthay, Michael A., Shaver, Ciara M., Bastarache, Julie A., Calfee, Carolyn S., Kerchberger, V. Eric, and Ware, Lorraine B.
- Published
- 2024
- Full Text
- View/download PDF
15. Acute Kidney Injury and Subsequent Cardiovascular Disease: Epidemiology, Pathophysiology, and Treatment
- Author
-
Chan, Ming-Jen and Liu, Kathleen D.
- Published
- 2024
- Full Text
- View/download PDF
16. Plasma Kidney Injury Molecule 1 in CKD: Findings From the Boston Kidney Biopsy Cohort and CRIC Studies
- Author
-
Schmidt, Insa M, Srivastava, Anand, Sabbisetti, Venkata, McMahon, Gearoid M, He, Jiang, Chen, Jing, Kusek, John W, Taliercio, Jonathan, Ricardo, Ana C, Hsu, Chi-yuan, Kimmel, Paul L, Liu, Kathleen D, Mifflin, Theodore E, Nelson, Robert G, Vasan, Ramachandran S, Xie, Dawei, Zhang, Xiaoming, Palsson, Ragnar, Stillman, Isaac E, Rennke, Helmut G, Feldman, Harold I, Bonventre, Joseph V, Waikar, Sushrut S, and Investigators, Chronic Kidney Disease Biomarkers Consortium and the CRIC Study
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Kidney Disease ,Clinical Research ,Renal and urogenital ,Good Health and Well Being ,Biomarkers ,Biopsy ,Boston ,Cohort Studies ,Cross-Sectional Studies ,Disease Progression ,Humans ,Kidney ,Prospective Studies ,Renal Insufficiency ,Chronic ,Chronic Kidney Disease Biomarkers Consortium and the CRIC Study Investigators ,Public Health and Health Services ,Urology & Nephrology ,Clinical sciences - Abstract
Rationale & objectivePlasma kidney injury molecule 1 (KIM-1) is a sensitive marker of proximal tubule injury, but its association with risks of adverse clinical outcomes across a spectrum of kidney diseases is unknown.Study designProspective, observational cohort study.Setting & participants524 individuals enrolled into the Boston Kidney Biopsy Cohort (BKBC) Study undergoing clinically indicated native kidney biopsy with biopsy specimens adjudicated for semiquantitative scores of histopathology by 2 kidney pathologists and 3,800 individuals with common forms of chronic kidney disease (CKD) enrolled into the Chronic Renal Insufficiency Cohort (CRIC) Study.ExposureHistopathologic lesions and clinicopathologic diagnosis in cross-sectional analyses, baseline plasma KIM-1 levels in prospective analyses.OutcomesBaseline plasma KIM-1 levels in cross-sectional analyses, kidney failure (defined as initiation of kidney replacement therapy) and death in prospective analyses.Analytical approachMultivariable-adjusted linear regression models tested associations of plasma KIM-1 levels with histopathologic lesions and clinicopathologic diagnoses. Cox proportional hazards models tested associations of plasma KIM-1 levels with future kidney failure and death.ResultsIn the BKBC Study, higher plasma KIM-1 levels were associated with more severe acute tubular injury, tubulointerstitial inflammation, and more severe mesangial expansion after multivariable adjustment. Participants with diabetic nephropathy, glomerulopathies, and tubulointerstitial disease had significantly higher plasma KIM-1 levels after multivariable adjustment. In the BKBC Study, CKD in 124 participants progressed to kidney failure and 85 participants died during a median follow-up time of 5 years. In the CRIC Study, CKD in 1,153 participants progressed to kidney failure and 1,356 participants died during a median follow-up time of 11.5 years. In both cohorts, each doubling of plasma KIM-1 level was associated with an increased risk of kidney failure after multivariable adjustment (hazard ratios of 1.19 [95% CI, 1.03-1.38] and 1.10 [95% CI, 1.06-1.15] for BKBC and CRIC, respectively). There was no statistically significant association of plasma KIM-1 levels with death in either cohort.LimitationsGeneralizability and unmeasured confounding.ConclusionsPlasma KIM-1 is associated with underlying tubulointerstitial and mesangial lesions and progression to kidney failure in 2 cohort studies of individuals with kidney diseases.
- Published
- 2022
17. Functional Transcriptomic Studies of Immune Responses and Endotoxin Tolerance in Early Human Sepsis
- Author
-
Leligdowicz, Aleksandra, Kamm, Jack, Kalantar, Katrina, Jauregui, Alejandra, Vessel, Kathryn, Caldera, Saharai, Serpa, Paula Hayakawa, Abbott, Jason, Fang, Xiaohui, Tian, Xiaoli, Prakash, Arun, Kangelaris, Kirsten Neudoerffer, Liu, Kathleen D, Calfee, Carolyn S, Langelier, Charles, and Matthay, Michael A
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Genetics ,Clinical Research ,Sepsis ,Infectious Diseases ,Hematology ,Aetiology ,4.1 Discovery and preclinical testing of markers and technologies ,2.1 Biological and endogenous factors ,Detection ,screening and diagnosis ,Inflammatory and immune system ,Endotoxin Tolerance ,Endotoxins ,Humans ,Immune Tolerance ,Immunity ,Inflammation ,Lipopolysaccharides ,Transcriptome ,Endotoxin tolerance ,immune system ,RNA expression ,sepsis ,Clinical Sciences ,Emergency & Critical Care Medicine ,Clinical sciences - Abstract
BackgroundLimited studies have functionally evaluated the heterogeneity in early ex vivo immune responses during sepsis. Our aim was to characterize early sepsis ex vivo functional immune response heterogeneity by studying whole blood endotoxin responses and derive a transcriptional metric of ex vivo endotoxin response.MethodsBlood collected within 24 h of hospital presentation from 40 septic patients was divided into two fractions and incubated with media (unstimulated) or endotoxin. Supernatants and cells were isolated, and responses measured using: supernatant cytokines, lung endothelial permeability after supernatant exposure, and RNA expression. A transcriptomic signature was derived in unstimulated cells to predict the ex vivo endotoxin response. The signature was tested in a separate cohort of 191 septic patients to evaluate for association with clinical outcome. Plasma biomarkers were quantified to measure in vivo host inflammation.ResultsEx vivo response to endotoxin varied and was unrelated to immunosuppression, white blood cell count, or the causative pathogen. Thirty-five percent of patients demonstrated a minimal response to endotoxin, suggesting early immunosuppression. High ex vivo cytokine production by stimulated blood cells correlated with increased in vitro pulmonary endothelial cell permeability and was associated with attenuated in vivo host inflammation. A four-gene signature of endotoxin response detectable without the need for a functional assay was identified. When tested in a separate cohort of septic patients, its expression was inversely associated with hospital mortality.ConclusionsAn attenuated ex vivo endotoxin response in early sepsis is associated with greater host in vivo inflammation and a worse clinical outcome.
- Published
- 2022
18. Fluid balance and renal replacement therapy initiation strategy: a secondary analysis of the STARRT-AKI trial
- Author
-
Wald, Ron, Kirkham, Brian, daCosta, Bruno R, Ghamarian, Ehsan, Adhikari, Neill KJ, Beaubien-Souligny, William, Bellomo, Rinaldo, Gallagher, Martin P, Goldstein, Stuart, Hoste, Eric AJ, Liu, Kathleen D, Neyra, Javier A, Ostermann, Marlies, Palevsky, Paul M, Schneider, Antoine, Vaara, Suvi T, and Bagshaw, Sean M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Kidney Disease ,Renal and urogenital ,Good Health and Well Being ,Humans ,Acute Kidney Injury ,Critical Illness ,Renal Replacement Therapy ,Water-Electrolyte Balance ,Water-Electrolyte Imbalance ,Acute kidney injury ,Renal replacement therapy ,Randomized controlled trial ,Fluid balance ,Clinical outcomes ,Medical and Health Sciences ,Emergency & Critical Care Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundAmong critically ill patients with acute kidney injury (AKI), earlier initiation of renal replacement therapy (RRT) may mitigate fluid accumulation and confer better outcomes among individuals with greater fluid overload at randomization.MethodsWe conducted a pre-planned post hoc analysis of the STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. We evaluated the effect of accelerated RRT initiation on cumulative fluid balance over the course of 14 days following randomization using mixed models after censoring for death and ICU discharge. We assessed the modifying effect of baseline fluid balance on the impact of RRT initiation strategy on key clinical outcomes. Patients were categorized in quartiles of baseline fluid balance, and the effect of accelerated versus standard RRT initiation on clinical outcomes was assessed in each quartile using risk ratios (95% CI) for categorical variables and mean differences (95% CI) for continuous variables.ResultsAmong 2927 patients in the modified intention-to-treat analysis, 2738 had available data on baseline fluid balance and 2716 (92.8%) had at least one day of fluid balance data following randomization. Over the subsequent 14 days, participants allocated to the accelerated strategy had a lower cumulative fluid balance compared to those in the standard strategy (4509 (- 728 to 11,698) versus 5646 (0 to 13,151) mL, p = 0.03). Accelerated RRT initiation did not confer greater 90-day survival in any of the baseline fluid balance quartiles (quartile 1: RR 1.11 (95% CI 0.92 to 1.34), quartile 2: RR 1.03 (0.87 to 1.21); quartile 3: RR 1.08 (95% CI 0.91 to 1.27) and quartile 4: RR 0.87 (95% CI 0.73 to 1.03), p value for trend 0.08).ConclusionsEarlier RRT initiation in critically ill patients with AKI conferred a modest attenuation of cumulative fluid balance. Nonetheless, among patients with greater fluid accumulation at randomization, accelerated RRT initiation did not have an impact on all-cause mortality.Trial registrationClinicalTrials.gov number, https://clinicaltrials.gov/ct2/show/NCT02568722 , registered October 6, 2015.
- Published
- 2022
19. Absence of long-term changes in urine biomarkers after AKI: findings from the CRIC study
- Author
-
McCoy, Ian E, Hsu, Jesse Y, Bonventre, Joseph V, Parikh, Chirag R, Go, Alan S, Liu, Kathleen D, Ricardo, Ana C, Srivastava, Anand, Cohen, Debbie L, He, Jiang, Chen, Jing, Rao, Panduranga S, Muiru, Anthony N, and Hsu, Chi-yuan
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Kidney Disease ,Clinical Research ,Renal and urogenital ,Good Health and Well Being ,Acute Kidney Injury ,Adult ,Biomarkers ,Creatinine ,Humans ,Kidney Function Tests ,Renal Insufficiency ,Chronic ,Acute kidney injury ,Chronic kidney disease ,Urology & Nephrology ,Clinical sciences ,Health services and systems ,Nursing - Abstract
BackgroundMechanisms by which AKI leads to CKD progression remain unclear. Several urine biomarkers have been identified as independent predictors of progressive CKD. It is unknown whether AKI may result in long-term changes in these urine biomarkers, which may mediate the effect of AKI on CKD progression.MethodsWe selected 198 episodes of hospitalized AKI (defined as peak/nadir inpatient serum creatinine values ≥ 1.5) among adult participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. We matched the best non-AKI hospitalization (unique patients) for each AKI hospitalization using pre-hospitalization characteristics including eGFR and urine protein/creatinine ratio. Biomarkers were measured in banked urine samples collected at annual CRIC study visits.ResultsUrine biomarker measurements occurred a median of 7 months before and 5 months after hospitalization. There were no significant differences in the change in urine biomarker-to-creatinine ratio between the AKI and non-AKI groups: KIM-1/Cr + 9% vs + 7%, MCP-1/Cr + 4% vs + 1%, YKL-40/Cr + 7% vs -20%, EGF/Cr -11% vs -8%, UMOD/Cr -2% vs -7% and albumin/Cr + 17% vs + 13% (all p > 0.05).ConclusionIn this cohort of adults with CKD, AKI did not associate with long-term changes in urine biomarkers.
- Published
- 2022
20. The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial
- Author
-
Monteiro, Ana Carolina Costa, Vangala, Sitaram, Wick, Katherine D, Delucchi, Kevin L, Siegel, Emily R, Thompson, B Taylor, Liu, Kathleen D, Sapru, Anil, Sinha, Pratik, and Matthay, Michael A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Patient Safety ,Clinical Trials and Supportive Activities ,Rare Diseases ,Clinical Research ,Good Health and Well Being ,APACHE ,Humans ,Kaplan-Meier Estimate ,Neuromuscular Blockade ,Prognosis ,Respiratory Distress Syndrome ,Ventilatory ratio ,VR ,ARDS ,Neuromuscular blockade ,APACHE-III ,ROSE trial ,NHLBI PETAL Network ,Medical and Health Sciences ,Emergency & Critical Care Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundThe ventilatory ratio (VR, [minute ventilation × PaCO2]/[predicted body weight × 100 × 37.5]) is associated with mortality in ARDS. The aims of this study were to test whether baseline disease severity or neuromuscular blockade (NMB) modified the relationship between VR and mortality.MethodsThis was a post hoc analysis of the PETAL-ROSE trial, which randomized moderate-to-severe ARDS patients to NMB or control. Survival among patients with different VR trajectories or VR cutoff above and below the median was assessed by Kaplan-Meier analysis. The relationships between single-day or 48-h VR trajectories with 28- or 90-day mortality were tested by logistic regression. Randomization allocation to NMB and markers of disease severity were tested as confounders by multivariable regression and interaction term analyses.ResultsPatients with worsening VR trajectories had significantly lower survival compared to those with improving VR (n = 602, p 2 (median) at day 1 had a significantly lower 90-day survival compared to patients with VR ≤ 2 (HR 1.36, 95% CI 1.10-1.69). VR at day 1 was significantly associated with 28-day mortality (OR = 1.40, 95% CI 1.15-1.72). There was no interaction between NMB and VR for 28-day mortality. APACHE-III had a significant interaction with VR at baseline for the outcome of 28-day mortality, such that the relationship between VR and mortality was stronger among patients with lower APACHE-III. There was a significant association between rising VR trajectory and mortality that was independent of NMB, baseline PaO2/FiO2 ratio and generalized markers of disease severity (Adjusted OR 1.81, 95% CI 1.28-2.84 for 28-day and OR 2.07 95% CI 1.41-3.10 for 90-day mortality). APACHE-III and NMB were not effect modifiers in the relationship between VR trajectory and mortality.ConclusionsElevated baseline and day 1 VR were associated with higher 28-day mortality. The relationship between baseline VR and mortality was stronger among patients with lower APACHE-III. APACHE-III was not an effect modifier for the relationship between VR trajectory and mortality, so that the VR trajectory may be optimally suited for prognostication and predictive enrichment. VR was not different between patients randomized to NMB or control, indicating that VR can be utilized without correcting for NMB.
- Published
- 2022
21. Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with progression to severe disease in hospitalized COVID-19
- Author
-
Wick, Katherine D, Leligdowicz, Aleksandra, Willmore, Andrew, Carrillo, Sidney A, Ghale, Rajani, Jauregui, Alejandra, Chak, Suzanna S, Nguyen, Viet, Lee, Deanna, Jones, Chayse, Dewar, Robin, Lane, H Clifford, Kangelaris, Kirsten N, Hendrickson, Carolyn M, Liu, Kathleen D, Sinha, Pratik, Erle, David J, Langelier, Charles R, Krummell, Matthew F, Woodruff, Prescott G, Calfee, Carolyn S, and Matthay, Michael A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Emerging Infectious Diseases ,Lung ,Infectious Diseases ,Prevention ,Clinical Research ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Infection ,Good Health and Well Being ,COVID-19 ,Humans ,Nucleocapsid ,RNA ,Viral ,SARS-CoV-2 ,COMET Consortium ,Medical and Health Sciences ,Emergency & Critical Care Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundStudies quantifying SARS-CoV-2 have focused on upper respiratory tract or plasma viral RNA with inconsistent association with clinical outcomes. The association between plasma viral antigen levels and clinical outcomes has not been previously studied. Our aim was to investigate the relationship between plasma SARS-CoV-2 nucleocapsid antigen (N-antigen) concentration and both markers of host response and clinical outcomes.MethodsSARS-CoV-2 N-antigen concentrations were measured in the first study plasma sample (D0), collected within 72 h of hospital admission, from 256 subjects admitted between March 2020 and August 2021 in a prospective observational cohort of hospitalized patients with COVID-19. The rank correlations between plasma N-antigen and plasma biomarkers of tissue damage, coagulation, and inflammation were assessed. Multiple ordinal regression was used to test the association between enrollment N-antigen plasma concentration and the primary outcome of clinical deterioration at one week as measured by a modified World Health Organization (WHO) ordinal scale. Multiple logistic regression was used to test the association between enrollment plasma N-antigen concentration and the secondary outcomes of ICU admission, mechanical ventilation at 28 days, and death at 28 days. The prognostic discrimination of an externally derived "high antigen" cutoff of N-antigen ≥ 1000 pg/mL was also tested.ResultsN-antigen on D0 was detectable in 84% of study participants. Plasma N-antigen levels significantly correlated with RAGE (r = 0.61), IL-10 (r = 0.59), and IP-10 (r = 0.59, adjusted p = 0.01 for all correlations). For the primary outcome of clinical status at one week, each 500 pg/mL increase in plasma N-antigen level was associated with an adjusted OR of 1.05 (95% CI 1.03-1.08) for worse WHO ordinal status. D0 plasma N-antigen ≥ 1000 pg/mL was 77% sensitive and 59% specific (AUROC 0.68) with a positive predictive value of 23% and a negative predictive value of 93% for a worse WHO ordinal scale at day 7 compared to baseline. D0 N-antigen concentration was independently associated with ICU admission and 28-day mechanical ventilation, but not with death at 28 days.ConclusionsPlasma N-antigen levels are readily measured and provide important insight into the pathogenesis and prognosis of COVID-19. The measurement of N-antigen levels early in-hospital course may improve risk stratification, especially for identifying patients who are unlikely to progress to severe disease.
- Published
- 2022
22. Healthy versus inflamed lung environments differentially affect mesenchymal stromal cells
- Author
-
Enes, Sara Rolandsson, Hampton, Thomas H, Barua, Jayita, McKenna, David H, dos Santos, Claudia C, Amiel, Eyal, Ashare, Alix, Liu, Kathleen D, Krasnodembskaya, Anna D, English, Karen, Stanton, Bruce A, Rocco, Patricia RM, Matthay, Michael A, and Weiss, Daniel J
- Subjects
Rare Diseases ,Acute Respiratory Distress Syndrome ,Stem Cell Research - Nonembryonic - Human ,Lung ,Stem Cell Research ,Clinical Research ,1.1 Normal biological development and functioning ,2.1 Biological and endogenous factors ,Underpinning research ,Aetiology ,Inflammatory and immune system ,Bronchoalveolar Lavage Fluid ,Humans ,Mesenchymal Stem Cell Transplantation ,Mesenchymal Stem Cells ,Respiratory Distress Syndrome ,Medical and Health Sciences ,Respiratory System - Abstract
BackgroundDespite increased interest in mesenchymal stromal cell (MSC)-based cell therapies for acute respiratory distress syndrome (ARDS), clinical investigations have not yet been successful and our understanding of the potential in vivo mechanisms of MSC actions in ARDS remains limited. ARDS is driven by an acute severe innate immune dysregulation, often characterised by inflammation, coagulation and cell injury. How this inflammatory microenvironment influences MSC functions remains to be determined.AimThe aim of this study was to comparatively assess how the inflammatory environment present in ARDS lungs versus the lung environment present in healthy volunteers alters MSC behaviour.MethodsClinical-grade human bone marrow-derived MSCs (hMSCs) were exposed to bronchoalveolar lavage fluid (BALF) samples obtained from ARDS patients or from healthy volunteers. Following exposure, hMSCs and their conditioned media were evaluated for a broad panel of relevant properties, including viability, levels of expression of inflammatory cytokines, gene expression, cell surface human leukocyte antigen expression, and activation of coagulation and complement pathways.ResultsPro-inflammatory, pro-coagulant and major histocompatibility complex (self-recognition) related gene expression was markedly upregulated in hMSCs exposed ex vivo to BALF obtained from healthy volunteers. These changes were less apparent and often opposite in hMSCs exposed to ARDS BALF samples.ConclusionThese data provide new insights into how hMSCs behave in healthy versus inflamed lung environments, and strongly suggest that the inflamed environment in ARDS induces hMSC responses that are potentially beneficial for cell survival and actions. This further highlights the need to understand how different disease environments affect hMSC functions.
- Published
- 2021
23. Changes in intensive care unit admission rates, organ support, and mortality in patients with acute myeloid leukaemia over a 12‐year period: a Danish nationwide cohort study
- Author
-
Maeng, Cecilie V, Østgård, Lene Sofie G, Christiansen, Christian F, and Liu, Kathleen D
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Good Health and Well Being ,Adult ,Comorbidity ,Confounding Factors ,Epidemiologic ,Denmark ,Humans ,Intensive Care Units ,Leukemia ,Myeloid ,Acute ,Odds Ratio ,Patient Admission ,Procedures and Techniques Utilization ,Registries ,Respiration ,Artificial ,acute myeloid leukaemia ,intensive care ,survival ,population-based ,organ support ,Cardiorespiratory Medicine and Haematology ,Immunology ,Cardiovascular medicine and haematology - Abstract
Changes in acute myeloid leukaemia (AML) treatment may affect requirement for admission to and treatments in intensive care units (ICUs). We evaluated trends in ICU admission, use of organ support, and 1-year mortality in Danish AML patients. Of 1417 AML patients diagnosed 2005-2016, 28.0% (n=397) were ICU-admitted within 3 years, with no major change in admission rate during the 12-year period. Use of mechanical ventilation and dialysis decreased (66.7% to 40.6%), while use of non-invasive ventilation increased (20.0% to 50.0%). Concurrently, 1-year mortality declined among all patients (36.0% in 2005 to 28.8% in 2016) and ICU-admitted patients (80.0% to 65.6%).
- Published
- 2021
24. Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative
- Author
-
Prowle, John R, Forni, Lui G, Bell, Max, Chew, Michelle S, Edwards, Mark, Grams, Morgan E, Grocott, Michael PW, Liu, Kathleen D, McIlroy, David, Murray, Patrick T, Ostermann, Marlies, Zarbock, Alexander, Bagshaw, Sean M, Bartz, Raquel, Bell, Samira, Bihorac, Azra, Gan, Tong J, Hobson, Charles E, Joannidis, Michael, Koyner, Jay L, Levett, Denny ZH, Mehta, Ravindra L, Miller, Timothy E, Mythen, Michael G, Nadim, Mitra K, Pearse, Rupert M, Rimmele, Thomas, Ronco, Claudio, Shaw, Andrew D, and Kellum, John A
- Subjects
Prevention ,Cardiovascular ,Patient Safety ,Clinical Research ,Kidney Disease ,Renal and urogenital ,Good Health and Well Being ,Acute Kidney Injury ,Humans ,Kidney ,Postoperative Complications ,Risk Factors ,Clinical Sciences ,Urology & Nephrology - Abstract
Postoperative acute kidney injury (PO-AKI) is a common complication of major surgery that is strongly associated with short-term surgical complications and long-term adverse outcomes, including increased risk of chronic kidney disease, cardiovascular events and death. Risk factors for PO-AKI include older age and comorbid diseases such as chronic kidney disease and diabetes mellitus. PO-AKI is best defined as AKI occurring within 7 days of an operative intervention using the Kidney Disease Improving Global Outcomes (KDIGO) definition of AKI; however, additional prognostic information may be gained from detailed clinical assessment and other diagnostic investigations in the form of a focused kidney health assessment (KHA). Prevention of PO-AKI is largely based on identification of high baseline risk, monitoring and reduction of nephrotoxic insults, whereas treatment involves the application of a bundle of interventions to avoid secondary kidney injury and mitigate the severity of AKI. As PO-AKI is strongly associated with long-term adverse outcomes, some form of follow-up KHA is essential; however, the form and location of this will be dictated by the nature and severity of the AKI. In this Consensus Statement, we provide graded recommendations for AKI after non-cardiac surgery and highlight priorities for future research.
- Published
- 2021
25. Regional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis
- Author
-
Vaara, Suvi T., Serpa Neto, Ary, Bellomo, Rinaldo, Adhikari, Neill K. J., Dreyfuss, Didier, Gallagher, Martin, Gaudry, Stephane, Hoste, Eric, Joannidis, Michael, Pettilä, Ville, Wang, Amanda Y., Kashani, Kianoush, Wald, Ron, Bagshaw, Sean M., Ostermann, Marlies, Bagshaw, Sean M, Wald, Ron, Adhikari, Neill K.J., Bellomo, Rinaldo, Dreyfuss, Didier, Du, Bin, Gallagher, Martin P., Gaudry, Stéphane, Hoste, Eric A., Lamontagne, François, Joannidis, Michael, Liu, Kathleen D., McAuley, Daniel F., McGuinness, Shay P., Nichol, Alistair D., Ostermann, Marlies, Palevsky, Paul M., Qiu, Haibo, Pettilä, Ville, Schneider, Antoine G., Smith, Orla M., Vaara, Suvi T., Weir, Matthew, Bellomo, Rinaldo, Eastwood, Glenn M., Peck, Leah, Young, Helen, Kruger, Peter, Laurie, Gordon, Saylor, Emma, Meyer, Jason, Venz, Ellen, Wetzig, Krista, French, Craig, McGain, Forbes, Mulder, John, Fennessy, Gerard, Koottayi, Sathyajith, Bates, Samantha, Towns, Miriam, Morgan, Rebecca, Tippett, Anna, Udy, Andrew, Mason, Chris, Licari, Elisa, Gantner, Dashiell, McClure, Jason, Nichol, Alistair, McCracken, Phoebe, Board, Jasmin, Martin, Emma, Vallance, Shirley, Young, Meredith, Vladic, Chelsey, McGloughlin, Steve, Gattas, David, Buhr, Heidi, Coles, Jennifer, Hutch, Debra, Wun, James, Cole, Louise, Whitehead, Christina, Lowrey, Julie, Masters, Kristy, Gresham, Rebecca, Campbell, Victoria, Gutierrez, David, Brailsford, Jane, Forbes, Loretta, Murray, Lauren, Maguire, Teena, NiChonghaile, Martina, Orford, Neil, Bone, Allison, Elderkin, Tania, Salerno, Tania, Chimunda, Tim, Fletcher, Jason, Broadfield, Emma, Porwal, Sanjay, Knott, Cameron, Boschert, Catherine, Smith, Julie, Richardson, Angus, Hill, Dianne, Duke, Graeme, Oziemski, Peter, Cegarra, Santiago, Chan, Peter, Welsh, Deborah, Hunter, Stephanie, Roodenburg, Owen, Dyett, John, Kokotsis, Nicos, Moser, Max, Yang, Yang, Padayachee, Laven, Vetro, Joseph, Gangopadhyay, Himangsu, Kaufman, Melissa, Ghosh, Angaj, Said, Simone, Patel, Alpesh, Bihari, Shailesh, Matheson, Elisha, Jin, Xia, Shrestha, Tapaswi, Schwartz, Kate, Gallagher, Martin P., Cross, Rosalba, Cheung, Winston, Wong, Helen, Kol, Mark, Shah, Asim, Wang, Amanda Y., Endre, Zoltan, Bradford, Celia, Janin, Pierre, Finfer, Simon, Diel, Naomi, Gatward, Jonathan, Hammond, Naomi, Delaney, Anthony, Bass, Frances, Yarad, Elizabeth, Buscher, Hergen, Reynolds, Claire, Baker, Nerilee, Joannidis, Michael, Bellmann, Romuald, Peer, Andreas, Hasslacher, Julia, Koglberger, Paul, Klein, Sebastian, Zotter, Klemens, Brandtner, Anna, Finkenstedt, Armin, Ditlbacher, Adelheid, Hartig, Frank, Fries, Dietmar, Bachler, Mirjam, Schenk, Bettina, Wagner, Martin, Staudinger, Thomas, Tiller, Esther, Schellongowski, Peter, Bojic, Andja, Hoste, Eric A., Bracke, Stephanie, De Crop, Luc, Vermeiren, Daisy, Thome, Fernando, Chiella, Bianca, Fendt, Lucia, Antunes, Veronica, Maisonneuve-Rosemont, Lafrance, Jean-Philippe, Lamontagne, François, D’Aragon, Frédérick, St-Arnaud, Charles, Mayette, Michael, Carbonnaeu, Élaine, Marchand, Joannie, Masse, Marie-Hélène, Ladouceur, Marilène, Turgeon, Alexis F., Lauzier, François, Bellemare, David, Langis Francoeur, Charles, LeBlanc, Guillaume, Guilbault, Gabrielle, Grenier, Stéphanie, Cloutier, Eve, Boivin, Annick, Delisle-Thibault, Charles, Giannakouros, Panagiota, Costerousse, Olivier, Cailhier, Jean-François, Carrier, François-Martin, Ghamraoui, Ali, Lebrasseur, Martine, Benettaib, Fatna, Salamé, Maya, Boumahni, Dounia, Tung Sia, Ying, Naud, Jean-François, Roy, Isabelle, Stelfox, Henry T., Ruddell, Stacey, Manns, Braden J., Duggan, Shelley, Carney, Dominic, Barchard, Jennifer, Whitlock, Richard P., Belley-Cote, Emilie, Savija, Nevena, Sabev, Alexandra, Campbell, Troy, Creary, Thais, Devereaux, Kelson, Brodutch, Shira, Rigatto, Claudio, Paunovic, Bojan, Mooney, Owen, Glybina, Anna, Harasemiw, Oksana, Di Nella, Michelle, Harmon, John, Mehta, Navdeep, Lakatos, Louis, Haslam, Nicole, Lellouche, Francois, Simon, Mathieu, Tung, Ying, Lizotte, Patricia, Bourchard, Pierre-Alexandre, Rochwerg, Bram, Karachi, Tim, Millen, Tina, Muscedere, John, Maslove, David, Gordon Boyd, J., Sibley, Stephanie, Drover, John, Hunt, Miranda, Georgescu, Ilinca, Wax, Randy, Lenga, Ilan, Sridhar, Kavita, Steele, Andrew, Fusco, Kelly, Ghate, Taneera, Tolibas, Michael, Robinson, Holly, Weir, Matthew A., Taneja, Ravi, Ball, Ian M., Garg, Amit, Campbell, Eileen, Ovsenek, Athena, Bagshaw, Sean M., van Diepen, Sean, Baig, Nadia, Magder, Sheldon, Yao, Han, Alam, Ahsan, Campisi, Josie, MacIntyre, Erika, Rokosh, Ella, Scherr, Kimberly, Lapinsky, Stephen, Mehta, Sangeeta, Shah, Sumesh, Niven, Daniel J., Stelfox, Henry T., Ruddell, Stacey, Russell, Michael, Jim, Kym, Brown, Gillian, Oxtoby, Kerry, Hall, Adam, Benoit, Luc, Sokolowski, Colleen, Prasad, Bhanu, Rao, Jag, Giebel, Shelley, Kutsogiannis, Demetrios J., Thompson, Patricia, Thompson, Tayne, Cirone, Robert, Kavikondala, Kanthi, Soth, Mark, Clarke, France, Takaoka, Alyson, Wald, Ron, Mazer, David, Burns, Karen, Friedrich, Jan, Klein, David, Sandhu, Gyan, Santos, Marlene, Khalid, Imrana, Hodder, Jennifer, Dodek, Peter, Ayas, Najib, Alcuaz, Victoria, Suen, Gabriel, Rewa, Oleksa, Singh, Gurmeet, Norris, Sean, Gibson, Neil, Arias, Castro, Shami, Aysha, Pelletier, Celine, Adhikari, Neill K.J., Zahirieh, Alireza, Amaral, Andre, Marinoff, Nicole, Kaur, Navjot, Perez, Adic, Wang, Jane, Haljan, Gregory, Condin, Christopher, McIntyre, Lauralyn, Gomes, Brigette, Porteous, Rebecca, Watpool, Irene, Hiremath, Swapnil, Clark, Edward, Herridge, Margaret S., Backhouse, Felicity, Elizabeth Wilcox, M., Walczak, Karolina, Ki, Vincent, Sharman, Asheer, Romano, Martin, Bagshaw, Sean M., Noel Gibney, R.T., Romanovsky, Adam S., Rewa, Oleksa, McCoshen, Lorena, Baig, Nadia, Wood, Gordon, Ovakim, Daniel, Auld, Fiona, Carney, Gayle, Duan, Meili, Ji, Xiaojun, Guo, Dongchen, Qi, Zhili, Lin, Jin, Zhang, Meng, Dong, Lei, Liu, Jingfeng, Liu, Pei, Zhi, Deyuan, Bai, Guoqiang, Qiu, Yu, Yang, Ziqi, Bai, Jing, Liu, Zhuang, Zhuang, Haizhou, Wang, Haiman, Li, Jian, Zhao, Mengya, Zhou, Xiao, Shi, Xianqing, Ye, Baning, Liu, Manli, Wu, Jing, Fu, Yongjian, Long, Dali, Pan, Yu, Wang, Jinlong, Mei, Huaxian, Zhang, Songsong, Wen, Mingxiang, Yang, Enyu, Mu, Sijie, Li, Jianquan, Hu, Tingting, Qin, Bingyu, Li, Min, Wang, Cunzhen, Dong, Xin, Wang, Kaiwu, Wang, Haibo, Yang, Jianxu, Du, Bin, Wang, Chuanyao, Wang, Dongxin, Li, Nan, Yu, Zhui, Xu, Song, Yao, Lan, Hou, Guo, Liu, Zhou, Lu, Liping, Lian, Yingtao, Wang, Chunting, Zhang, Jichen, Ding, Ruiqi, Qi, Guoqing, Wang, Qizhi, Wang, Peng, Meng, Zhaoli, Chen, Man, Hu, Xiaobo, He, Xiandi, Zhao, Shibing, Hang, Lele, Li, Rui, Qin, Suhui, Lu, Kun, Dun, Shijuan, Liu, Cheng, Zhou, Qi, Chen, Zhenzhen, Mei, Jing, Zhang, Minwei, Xu, Hao, Lin, Jincan, Shi, Qindong, Fu, Lijuan, Zeng, Qinjing, Ma, Hongye, Yan, Jinqi, Gao, Lan, Liu, Hongjuan, Zhang, Lei, Li, Hao, He, Xiaona, Fan, Jingqun, Guo, Litao, Liu, Yu, Wang, Xue, Sun, Jingjing, Liu, Zhongmin, Yang, Juan, Ding, Lili, Sheng, Lulu, Liu, Xingang, Yan, Jie, Wang, Quihui, Wang, Yifeng, Zhao, Dan, Zhao, Shuangping, Hu, Chenghuan, Li, Jing, Deng, Fuxing, Qiu, Haibo, Yang, Yi, Mo, Min, Pan, Chun, Wu, Changde, Huang, Yingzi, Huang, Lili, Liu, Airan, Pettilä, Ville, Vaara, Suvi T., Korhonen, Anna-Maija, Törnblom, Sanna, Sutinen, Sari, Pettilä, Leena, Heinonen, Jonna, Lappi, Eliria, Suhonen, Taria, Karlsson, Sari, Hoppu, Sanna, Jalkanen, Ville, Kuitunen, Anne, Levoranta, Markus, Långsjö, Jaakko, Ristimäki, Sanna, Malila, Kaisa, Wootten, Anna, Varila, Simo, Järvisalo, Mikko J, Inkinen, Outi, Kentala, Satu, Leivo, Keijo, Haltia, Paivi, Dreyfuss, Didier, Ricard, Jean-Damien, Messika, Jonathan, Tiagarajah, Abirami, Emery, Malo, Dechanet, Aline, Gernez, Coralie, Roux, Damien, Martin-Lefevre, Laurent, Fiancette, Maud, Vinatier, Isabelle, Claude Lacherade, Jean, Colin, Gwenhaël, Lebert, Christine, Azais, Marie-Ange, Yehia, Aihem, Pouplet, Caroline, Henry- Lagarrigue, Matthieu, Seguin, Amélie, Crosby, Laura, Maizel, Julien, Titeca-Beauport, Dimitri, Combes, Alain, Nieszkowska, Ania, Masi, Paul, Demoule, Alexandre, Mayaux, Julien, Dres, Martin, Morawiec, Elise, Decalvele, Maxens, Demiri, Suela, Faure, Morgane, Marios, Clémence, Mallet, Maxime, Amélie Ordon, Marie, Morizot, Laura, Cantien, Marie, Pousset, François, Gaudry, Stéphane, Poirson, Florent, Cohen, Yves, Argaud, Laurent, Cour, Martin, Bitker, Laurent, Simon, Marie, Hernu, Romain, Baudry, Thomas, De La Salle, Sylvie, Robine, Adrien, Sedillot, Nicholas, Tchenio, Xavier, Bouisse, Camille, Roux, Sylvie, Barbar, Davide, Trusson, Rémi, Tamion, Fabienne, Grangé, Steven, Carpentier, Dorothée, Chevrel, Guillaume, Ensenyat-Martin, Luis, Marque, Sophie, Quenot, Jean-Pierre, Andreu, Pascal, Dargent, Auguste, Large, Audrey, Chudeau, Nicolas, Landais, Mickael, Derrien, Benoit, Christophe Callahan, Jean, Guitton, Christophe, Le Moal, Charlène, Robert, Alain, Asehnoune, Karim, Cinotti, Raphaël, Grillot, Nicolas, Demeure, Dominique, Vinsonneau, Christophe, Rahmani, Imen, Marzouk, Mehdi, Dekeyser, Thibault, Sejourne, Caroline, Verlay, Mélanie, Thevenin, Fabienne, Delecolle, Lucie, Didier Thevenin, Lens, Souweine, Bertrand, Coupez, Elisabeth, Adda, Mireille, Eraldi, Jean-Pierre, Marchalot, Antoine, De Prost, Nicolas, Mekontso Dessap, Armand, Razazi, Keyvan, Meziani, Ferhat, Boisrame-Helms, Julie, Clere-Jehl, Raphael, Delabranche, Xavier, Kummerlen, Christine, Merdji, Hamid, Monnier, Alexandra, Rabouel, Yannick, Rahmani, Hassene, Allam, Hayat, Chenaf, Samir, Franja, Vincenta, Pons, Bertrand, Carles, Michel, Martino, Frédéric, Richard, Régine, Zuber, Benjamin, Lacave, Guillaume, Lakhal, Karim, Rozec, Bertrand, Dang Van, Hoa, Boulet, Éric, Dubos, René, Fadel, Fouad, Cleophax, Cedric, Dufour, Nicolas, Grant, Caroline, Thuong, Marie, Reignier, Jean, Canet, Emmanuel, Nicolet, Laurent, Boulain, Thierry, Nay, Mai-Anh, Benzekri, Dalila, Barbier, François, Bretagnol, Anne, Kamel, Toufik, Mathonnet, Armelle, Muller, Grégoire, Skarzynski, Marie, Rossi, Julie, Pradet, Amandine, Dos Santos, Sandra, Guery, Aurore, Muller, Lucie, Felix, Luis, Bohé, Julien, Thiéry, Guillaume, Aissaoui, Nadia, Vimpere, Damien, Commeureuc, Morgane, Diehl, Jean-Luc, Guerot, Emmanuel, Liangos, Orfeas, Wittig, Monika, Zarbock, Alexander, Küllmar, Mira, van Waegeningh, Thomas, Rosenow, Nadine, Nichol, Alistair D., Brickell, Kathy, Doran, Peter, Murray, Patrick T., Landoni, Giovanni, Lembo, Rosalba, Zangrillo, Alberto, Monti, Giacomo, Tozzi, Margherita, Marzaroli, Matteo, Lombardi, Gaetano, Paternoster, Gianluca, Vitiello, Michelangelo, McGuinness, Shay, Parke, Rachael, Butler, Magdalena, Gilder, Eileen, Cowdrey, Keri-Anne, Wallace, Samantha, Hallion, Jane, Woolett, Melissa, Neal, Philippa, Duffy, Karina, Long, Stephanie, McArthur, Colin, Simmonds, Catherine, Chen, Yan, McConnochie, Rachael, Newby, Lynette, Knight, David, Henderson, Seton, Mehrtens, Jan, Morgan, Stacey, Morris, Anna, Vander Hayden, Kymbalee, Burke, Tara, Bailey, Matthew, Freebairn, Ross, Chadwick, Lesley, Park, Penelope, Rolls, Christine, Thomas, Liz, Buehner, Ulrike, Williams, Erin, Albrett, Jonathan, Kirkham, Simon, Jackson, Carolyn, Browne, Troy, Goodson, Jennifer, Jackson, David, Houghton, James, Callender, Owen, Higson, Vicki, Keet, Owen, Dominy, Clive, Young, Paul, Hunt, Anna, Judd, Harriet, Lawrence, Cassie, Olatunji, Shaanti, Robertson, Yvonne, Latimer-Bell, Charlotte, Hendry, Deborah, Mckay-Vucago, Agnes, Beehre, Nina, Lesona, Eden, Navarra, Leanlove, Robinson, Chelsea, Jang, Ryan, Junge, Andrea, Lambert, Bridget, Schneider, Antoine G., Thibault, Michel, Eckert, Philippe, Kissling, Sébastien, Polychronopoulos, Erietta, Poli, Elettra, Altarelli, Marco, Schnorf, Madeleine, Abed Mallaird, Samia, Heidegger, Claudia, Perret, Aurelie, Montillier, Philippe, Sangla, Frederic, Neils, Seigenthaller, De Watteville, Aude, Phull, Mandeep-Kaur, George, Aparna, Hussain, Nauman, Pogreban, Tatiana, Lobaz, Steve, Daniels, Alison, Cunningham, Mishell, Kerr, Deborah, Nicholson, Alice, Shanmugasundaram, Pradeep, Abrams, Judith, Manso, Katarina, Hambrook, Geraldine, McKerrow, Elizabeth, Salva, Juvy, Foulkes, Stephen, Wise, Matthew, Morgan, Matt, Brooks, Jenny, Cole, Jade, Michelle Davies, Tracy, Hill, Helen, Thomas, Emma, Vizcaychipi, Marcela, Baharlo, Behrad, Carungcong, Jaime, Costa, Patricia, Martins, Laura, Kapoor, Ritoo, Hazelton, Tracy, Moon, Angela, Musselwhite, Janine, Shelley, Ben, McCall, Philip, Ostermann, Marlies, Arbane, Gill, Bociek, Aneta, Marotti, Martina, Lim, Rosario, Campos, Sara, Grau Novellas, Neus, Cennamo, Armando, Slack, Andrew, Wyncoll, Duncan, Camporota, Luigi, Sparkes, Simon, Tilley, Rosalinde, Rattray, Austin, Moreland, Gayle, Duffy, Jane, McGonigal, Elizabeth, Hopkins, Philip, Finney, Clare, Smith, John, Noble, Harriet, Watson, Hayley, Harris, Claire-Louise, Clarey, Emma, Corcoran, Eleanor, Beck, James, Howcroft, Clare, Youngs, Nora, Wilby, Elizabeth, Ogg, Bethan, Wolverson, Adam, Lee, Sandra, Butler, Susie, Okubanjo, Maryanne, Hindle, Julia, Welters, Ingeborg, Williams, Karen, Johnson, Emily, Patrick-Heselton, Julie, Shaw, David, Waugh, Victoria, Stewart, Richard, Mwaura, Esther, Wren, Lynn, Mew, Louise, Sutherland, Sara-Beth, Adderley, Jane, Ruddy, Jim, Harkins, Margaret, Kaye, Callum, Scott, Teresa, Mitchell, Wendy, Anderson, Felicity, Willox, Fiona, Jagannathan, Vijay, Clark, Michele, Purv, Sarah, Sharman, Andrew, Meredith, Megan, Ryan, Lucy, Conner, Louise, Peters, Cecilia, Harvey, Dan, Roshdy, Ashraf, Collins, Amy, Sim, Malcolm, Henderson, Steven, Chee, Nigel, Pitts, Sally, Bowman, Katie, Dilawershah, Maria, Vamplew, Luke, Howe, Elizabeth, Rogers, Paula, Hernandez, Clara, Prendergast, Clara, Benton, Jane, Rosenberg, Alex, Forni, Lui G., Grant, Alice, Carvelli, Paula, Raithatha, Ajay, Bird, Sarah, Richardson, Max, Needham, Matthew, Hirst, Claire, Ball, Jonathan, Leaver, Susannah, Howlett, Luisa, Castro Delgado, Carlos, Farnell-Ward, Sarah, Farrah, Helen, Gray, Geraldine, Joseph, Gipsy, Robinson, Francesca, Tridente, Ascanio, Harrop, Clare, Shuker, Karen, McLaughlan, Derek, Ramsey, Judith, Meehan, Sharon, Oliver Rose, Bernd, Reece-Anthony, Rosie, Gurung, Babita, Whitehouse, Tony, Snelson, Catherine, Veenith, Tonny, Johnston, Andy, Cooper, Lauren, Carrera, Ron, Ellis, Karen, Fellows, Emma, Harkett, Samanth, Bergin, Colin, Spruce, Elaine, Despy, Liesl, Goundry, Stephanie, Dooley, Natalie, Mason, Tracy, Clark, Amy, Dignam, Gemma, Ward, Geraldine, Attwood, Ben, Parsons, Penny, Mason, Sophie, Margarson, Michael, Lord, Jenny, McGlone, Philip, Hodgson, Luke E., Chadbourn, Indra, Gomez, Raquel, Margalef, Jordi, Pretorius, Rinus, Hamshere, Alexandra, Carter, Joseph, Cahill, Hazel, Grainger, Lia, Howard, Kate, Forshaw, Greg, Guy, Zoe, Kashani, Kianoush B., Albright, Robert C., Amsbaugh, Amy, Stoltenberg, Anita, Niven, Alexander S., Lynch, Matthew, O’Mara, AnnMarie, Naeem, Syed, Sharif, Sairah, McKenney Goulart, Joyce, Lynch, Matthew, O’Mara, AnnMarie, Naeem, Syed, Sharif, Sairah, McKenney Goulart, Joyce, Tolwani, Ashita, Lyas, Claretha, Latta, Laura, Bihorac, Azra, Hashemighouchani, Haleh, Efron, Philip, Ruppert, Matthew, Cupka, Julie, Kiley, Sean, Carson, Joshua, White, Peggy, Omalay, George, Brown, Sherry, Velez, Laura, Marceron, Alina, Neyra, Javier A., Carlos Aycinena, Juan, Elias, Madona, Ortiz-Soriano, Victor M., Hauschild, Caroline, and Dorfman, Robert
- Published
- 2024
- Full Text
- View/download PDF
26. The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events
- Author
-
Menez, Steven, Wen, Yumeng, Xu, Leyuan, Moledina, Dennis G., Thiessen-Philbrook, Heather, Hu, David, Obeid, Wassim, Bhatraju, Pavan K., Ikizler, T. Alp, Siew, Edward D., Chinchilli, Vernon M., Garg, Amit X., Go, Alan S., Liu, Kathleen D., Kaufman, James S., Kimmel, Paul L., Himmelfarb, Jonathan, Coca, Steven G., Cantley, Lloyd G., and Parikh, Chirag R.
- Published
- 2023
- Full Text
- View/download PDF
27. Identifying the Sickest During Triage: Using Point‐of‐Care Severity Scores to Predict Prognosis in Emergency Department Patients With Suspected Sepsis
- Author
-
Prasad, Priya A, Fang, Margaret C, Martinez, Sandra P, Liu, Kathleen D, and Kangelaris, Kirsten N
- Subjects
Health Services and Systems ,Health Sciences ,Health Services ,Sepsis ,Infectious Diseases ,Hematology ,Patient Safety ,Clinical Research ,Emergency Care ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Infection ,Inflammatory and immune system ,Good Health and Well Being ,Adult ,Emergency Service ,Hospital ,Hospital Mortality ,Humans ,Organ Dysfunction Scores ,Point-of-Care Systems ,Prognosis ,ROC Curve ,Retrospective Studies ,Triage ,Clinical Sciences ,General & Internal Medicine ,Health services and systems ,Nursing - Abstract
BackgroundSepsis progresses rapidly and is associated with considerable morbidity and mortality. Bedside risk stratification scores can quickly identify patients at greatest risk of poor outcomes; however, there is lack of consensus on the best scale to use.ObjectiveTo compare the ability of quick Sequential Organ Failure Assessment (qSOFA), the National Early Warning System (NEWS2), and the Shock Index-which does not require mental status assessment-to predict poor outcomes among patients with suspected sepsis during triage.Design, setting, and participantsRetrospective cohort study of adults presenting to an academic emergency department (ED) from June 2012 to December 2018 who had blood cultures and intravenous antibiotics within 24 hours.Main outcomes and measuresClinical data were collected from the electronic health record. Patients were considered positive at qSOFA ≥2, Shock Index >0.7, or NEWS2 ≥5 scores. We calculated test characteristics and area under the receiver operating characteristics curves (AUROCs) to predict in-hospital mortality and ED-to-intensive care unit (ICU) admission.ResultsWe included 23,837 ED patients; 1,921(8.1%) were qSOFA-positive, 4,273 (17.9%) Shock Index-positive, and 11,832 (49.6%) NEWS2-positive. There were 1,427 (6.0%) deaths and 3,149 (13.2%) ED-to-ICU admissions in the sample. NEWS2 had the highest sensitivity for in-hospital mortality (76.0%) and ED-to-ICU admission (78.9%). qSOFA had the highest specificity for in-hospital mortality (93.4%) and ED-to-ICU admission (95.2%). Shock Index exhibited the highest AUROC for in-hospital mortality (0.648; 95 CI, 0.635-0.662) and ED-to-ICU admission (0.680; 95% CI, 0.617-0.689). Test characteristics were similar among those with sepsis.ConclusionsInstitution priorities should drive score selection, balancing sensitivity and specificity. In our study, qSOFA was highly specific and NEWS2 was the most sensitive for ruling out patients at high risk. Performance of the Shock Index fell between qSOFA and NEWS2 and could be considered because it is easy to implement.
- Published
- 2021
28. Plasma Metabolites in Early Sepsis Identify Distinct Clusters Defined by Plasma Lipids.
- Author
-
Rogers, Angela J, Leligdowicz, Aleksandra, Contrepois, Kévin, Jauregui, Alejandra, Vessel, Kathryn, Deiss, Thomas J, Belzer, Annika, Liu, Tom, Lippi, Matthew, Ke, Serena, Ross, Erin, Zhou, Hanjing, Hendrickson, Carolyn, Gomez, Antonio, Sinha, Pratik, Kangelaris, Kirsten N, Liu, Kathleen D, Calfee, Carolyn S, and Matthay, Michael A
- Subjects
acute respiratory distress syndrome ,clustering ,metabolomics ,phenotype ,sepsis ,Infectious Diseases ,Clinical Research ,Hematology ,Sepsis ,4.1 Discovery and preclinical testing of markers and technologies ,Inflammatory and immune system ,Infection - Abstract
Unbiased global metabolomic profiling has not been used to identify distinct subclasses in patients with early sepsis and sepsis-associated acute respiratory distress syndrome. In this study, we examined whether the plasma metabolome reflects systemic illness in early sepsis and in acute respiratory distress syndrome.DesignPlasma metabolites were measured in subjects with early sepsis.SettingPatients were admitted from the emergency department to the ICU in a plasma sample collected within 24 hours of ICU admission. Metabolic profiling of 970 metabolites was performed by Metabolon (Durham, NC). Hierarchical clustering and partial least squares discriminant clustering were used to identify distinct clusters among patients with early sepsis and sepsis-associated acute respiratory distress syndrome.InterventionsNone.Measurements and main resultsAmong critically ill patients with early sepsis (n = 197), three metabolically distinct subgroups were identified, with metabolic subtype driven by plasma lipids. Group 1, with 45 subjects (23% of cohort), had increased 60-day mortality (odds ratio, 2; 95% CI, 0.99-4.0; p = 0.04 for group 1 vs all others). This group also had higher rates of vasopressor-dependent shock, acute kidney injury, and met Berlin acute respiratory distress syndrome criteria more often (all p < 0.05). Conversely, metabolic group 3, with 76 subjects (39% of cohort), had the lowest risk of 60-day mortality (odds ratio, 0.44; 95% CI, 0.22-0.86; p = 0.01) and lower rates of organ dysfunction as reflected in a lower Simplified Acute Physiology Score II (p < 0.001). In contrast, global metabolomic profiling did not separate patient with early sepsis with moderate-to-severe acute respiratory distress syndrome (n = 78) from those with sepsis without acute respiratory distress syndrome (n = 75).ConclusionsPlasma metabolomic profiling in patients with early sepsis identified three metabolically distinct groups that were characterized by different plasma lipid profiles, distinct clinical phenotypes, and 60-day mortality. Plasma metabolites did not distinguish patients with early sepsis who developed acute respiratory distress syndrome from those who did not.
- Published
- 2021
29. Achieved blood pressure post-acute kidney injury and risk of adverse outcomes after AKI: A prospective parallel cohort study.
- Author
-
McCoy, Ian, Brar, Sandeep, Liu, Kathleen D, Go, Alan S, Hsu, Raymond K, Chinchilli, Vernon M, Coca, Steven G, Garg, Amit X, Himmelfarb, Jonathan, Ikizler, T Alp, Kaufman, James, Kimmel, Paul L, Lewis, Julie B, Parikh, Chirag R, Siew, Edward D, Ware, Lorraine B, Zeng, Hui, Hsu, Chi-Yuan, and Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study investigators
- Subjects
Assessment ,Serial Evaluation ,and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study investigators ,AKI ,blood pressure ,hypertension ,Kidney Disease ,Cardiovascular ,Clinical Research ,Patient Safety ,2.1 Biological and endogenous factors ,2.4 Surveillance and distribution ,Renal and urogenital ,Urology & Nephrology ,Clinical Sciences - Abstract
BackgroundThere has recently been considerable interest in better understanding how blood pressure should be managed after an episode of hospitalized AKI, but there are scant data regarding the associations between blood pressure measured after AKI and subsequent adverse outcomes. We hypothesized that among AKI survivors, higher blood pressure measured three months after hospital discharge would be associated with worse outcomes. We also hypothesized these associations between blood pressure and outcomes would be similar among those who survived non-AKI hospitalizations.MethodsWe quantified how systolic blood pressure (SBP) observed three months after hospital discharge was associated with risks of subsequent hospitalized AKI, loss of kidney function, mortality, and heart failure events among 769 patients in the prospective ASSESS-AKI cohort study who had hospitalized AKI. We repeated this analysis among the 769 matched non-AKI ASSESS-AKI enrollees. We then formally tested for AKI interaction in the full cohort of 1538 patients to determine if these associations differed among those who did and did not experience AKI during the index hospitalization.ResultsAmong 769 patients with AKI, 42 % had subsequent AKI, 13 % had loss of kidney function, 27 % died, and 18 % had heart failure events. SBP 3 months post-hospitalization did not have a stepwise association with the risk of subsequent AKI, loss of kidney function, mortality, or heart failure events. Among the 769 without AKI, there was also no stepwise association with these risks. In formal interaction testing using the full cohort of 1538 patients, hospitalized AKI did not modify the association between post-discharge SBP and subsequent risks of adverse clinical outcomes.ConclusionsContrary to our first hypothesis, we did not observe that higher stepwise blood pressure measured three months after hospital discharge with AKI was associated with worse outcomes. Our data were consistent with our second hypothesis that the association between blood pressure measured three months after hospital discharge and outcomes among AKI survivors is similar to that observed among those who survived non-AKI hospitalizations.
- Published
- 2021
30. Causes and attributable fraction of death from ARDS in inflammatory phenotypes of sepsis
- Author
-
Evrard, Bruno, Sinha, Pratik, Delucchi, Kevin, Hendrickson, Carolyn M., Kangelaris, Kirsten N., Liu, Kathleen D., Willmore, Andrew, Wu, Nelson, Neyton, Lucile, Schmiege, Emma, Gomez, Antonio, Kerchberger, V. Eric, Zalucky, Ann, Matthay, Michael A., Ware, Lorraine B., and Calfee, Carolyn S.
- Published
- 2024
- Full Text
- View/download PDF
31. Rapidly improving ARDS differs clinically and biologically from persistent ARDS
- Author
-
Valda Toro, Patricia L., Willmore, Andrew, Wu, Nelson E., Delucchi, Kevin L., Jauregui, Alejandra, Sinha, Pratik, Liu, Kathleen D., Hendrickson, Carolyn M., Sarma, Aartik, Neyton, Lucile P. A., Leligdowicz, Aleksandra, Langelier, Charles R., Zhuo, Hanjing, Jones, Chayse, Kangelaris, Kirsten N., Gomez, Antonio D., Matthay, Michael A., and Calfee, Carolyn S.
- Published
- 2024
- Full Text
- View/download PDF
32. Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial
- Author
-
Alipanah-Lechner, Narges, Hurst-Hopf, James, Delucchi, Kevin, Swigart, Lamorna, Willmore, Andrew, LaCombe, Benjamin, Dewar, Robin, Lane, H. Clifford, Lallemand, Perrine, Liu, Kathleen D., Esserman, Laura, Matthay, Michael A., and Calfee, Carolyn S.
- Published
- 2024
- Full Text
- View/download PDF
33. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials
- Author
-
Sinha, Pratik, Kerchberger, V Eric, Willmore, Andrew, Chambers, Julia, Zhuo, Hanjing, Abbott, Jason, Jones, Chayse, Wickersham, Nancy, Wu, Nelson, Neyton, Lucile, Langelier, Charles R, Mick, Eran, He, June, Jauregui, Alejandra, Churpek, Matthew M, Gomez, Antonio D, Hendrickson, Carolyn M, Kangelaris, Kirsten N, Sarma, Aartik, Leligdowicz, Aleksandra, Delucchi, Kevin L, Liu, Kathleen D, Russell, James A, Matthay, Michael A, Walley, Keith R, Ware, Lorraine B, and Calfee, Carolyn S
- Published
- 2023
- Full Text
- View/download PDF
34. Recovery of kidney function after dialysis initiation in children and adults in the US: A retrospective study of United States Renal Data System data.
- Author
-
Ku, Elaine, Hsu, Raymond K, Johansen, Kirsten L, McCulloch, Charles E, Mitsnefes, Mark, Grimes, Barbara A, and Liu, Kathleen D
- Subjects
General & Internal Medicine ,Medical and Health Sciences - Abstract
BackgroundLittle is known about factors associated with recovery of kidney function-and return to dialysis independence-or temporal trends in recovery after starting outpatient dialysis in the United States. Understanding the characteristics of individuals who may have the potential to recover kidney function may promote better recognition of such events. The goal of this study was to determine factors associated with recovery of kidney function in children compared with adults starting dialysis in the US.Methods and findingsWe determined factors associated with recovery of kidney function-defined as survival and discontinuation of dialysis for ≥90-day period-in children versus adults who started maintenance dialysis between 1996 and 2015 according to the United States Renal Data System (USRDS) followed through 2016 in a retrospective cohort study. We also examined temporal trends in recovery rates over the last 2 decades in this cohort. Among 1,968,253 individuals included for study, the mean age was 62.6 ± 15.8 years, and 44% were female. Overall, 4% of adults (83,302/1,953,881) and 4% of children (547/14,372) starting dialysis in the outpatient setting recovered kidney function within 1 year. Among those who recovered, the median time to recovery was 73 days (interquartile range [IQR] 43-131) in adults and 100 days (IQR 56-189) in children. Accounting for the competing risk of death, children were less likely to recover kidney function compared with adults (sub-hazard ratio [sub-HR] 0.81; 95% CI 0.74-0.89, p-value
- Published
- 2021
35. Biomarkers of inflammation and repair in kidney disease progression
- Author
-
Puthumana, Jeremy, Thiessen-Philbrook, Heather, Xu, Leyuan, Coca, Steven G, Garg, Amit X, Himmelfarb, Jonathan, Bhatraju, Pavan K, Ikizler, Talat Alp, Siew, Edward, Ware, Lorraine B, Liu, Kathleen D, Go, Alan S, Kaufman, James S, Kimmel, Paul L, Chinchilli, Vernon M, Cantley, Lloyd, and Parikh, Chirag R
- Subjects
Kidney Disease ,Clinical Research ,4.2 Evaluation of markers and technologies ,2.1 Biological and endogenous factors ,Detection ,screening and diagnosis ,Aetiology ,Renal and urogenital ,Acute Kidney Injury ,Aged ,Animals ,Biomarkers ,Chemokine CCL2 ,Chitinase-3-Like Protein 1 ,Disease Models ,Animal ,Disease Progression ,Female ,Follow-Up Studies ,Glomerular Filtration Rate ,Humans ,Inflammation ,Male ,Mice ,Middle Aged ,Renal Insufficiency ,Chronic ,Chronic kidney disease ,Clinical practice ,Molecular diagnosis ,Nephrology ,Medical and Health Sciences ,Immunology - Abstract
INTRODUCTIONAcute kidney injury and chronic kidney disease (CKD) are common in hospitalized patients. To inform clinical decision making, more accurate information regarding risk of long-term progression to kidney failure is required.METHODSWe enrolled 1538 hospitalized patients in a multicenter, prospective cohort study. Monocyte chemoattractant protein 1 (MCP-1/CCL2), uromodulin (UMOD), and YKL-40 (CHI3L1) were measured in urine samples collected during outpatient follow-up at 3 months. We followed patients for a median of 4.3 years and assessed the relationship between biomarker levels and changes in estimated glomerular filtration rate (eGFR) over time and the development of a composite kidney outcome (CKD incidence, CKD progression, or end-stage renal disease). We paired these clinical studies with investigations in mouse models of renal atrophy and renal repair to further understand the molecular basis of these markers in kidney disease progression.RESULTSHigher MCP-1 and YKL-40 levels were associated with greater eGFR decline and increased incidence of the composite renal outcome, whereas higher UMOD levels were associated with smaller eGFR declines and decreased incidence of the composite kidney outcome. A multimarker score increased prognostic accuracy and reclassification compared with traditional clinical variables alone. The mouse model of renal atrophy showed greater Ccl2 and Chi3l1 mRNA expression in infiltrating macrophages and neutrophils, respectively, and evidence of progressive renal fibrosis compared with the repair model. The repair model showed greater Umod expression in the loop of Henle and correspondingly less fibrosis.CONCLUSIONSBiomarker levels at 3 months after hospitalization identify patients at risk for kidney disease progression.FUNDINGNIH.
- Published
- 2021
36. A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death.
- Author
-
Ikizler, T Alp, Parikh, Chirag R, Himmelfarb, Jonathan, Chinchilli, Vernon M, Liu, Kathleen D, Coca, Steven G, Garg, Amit X, Hsu, Chi-Yuan, Siew, Edward D, Wurfel, Mark M, Ware, Lorraine B, Faulkner, Georgia Brown, Tan, Thida C, Kaufman, James S, Kimmel, Paul L, Go, Alan S, and ASSESS-AKI Study Investigators
- Subjects
ASSESS-AKI Study Investigators ,Kidney ,Humans ,Cardiovascular Diseases ,Glomerular Filtration Rate ,Aftercare ,Patient Discharge ,Risk Factors ,Prospective Studies ,Adult ,Acute Kidney Injury ,acute kidney injury ,acute renal failure ,cardiovascular disease ,chronic kidney disease ,heart failure ,mortality ,Cardiovascular ,Clinical Research ,Kidney Disease ,Aging ,Renal and urogenital ,Urology & Nephrology ,Clinical Sciences - Abstract
Acute kidney injury (AKI) has been reported to be associated with excess risks of death, kidney disease progression and cardiovascular events although previous studies have important limitations. To further examine this, we prospectively studied adults from four clinical centers surviving three months and more after hospitalization with or without AKI who were matched on center, pre-admission CKD status, and an integrated priority score based on age, prior cardiovascular disease or diabetes mellitus, preadmission estimated glomerular filtration rate (eGFR) and treatment in the intensive care unit during the index hospitalization between December 2009-February 2015, with follow-up through November 2018. All participants had assessments of kidney function before (eGFR) and at three months and annually (eGFR and proteinuria) after the index hospitalization. Associations of AKI with outcomes were examined after accounting for pre-admission and three-month post-discharge factors. Among 769 AKI (73% Stage 1, 14% Stage 2, 13% Stage 3) and 769 matched non-AKI adults, AKI was associated with higher adjusted rates of incident CKD (adjusted hazard ratio 3.98, 95% confidence interval 2.51-6.31), CKD progression (2.37,1.28-4.39), heart failure events (1.68, 1.22-2.31) and all-cause death (1.78, 1.24-2.56). AKI was not associated with major atherosclerotic cardiovascular events in multivariable analysis (0.95, 0.70-1.28). After accounting for degree of kidney function recovery and proteinuria at three months after discharge, the associations of AKI with heart failure (1.13, 0.80-1.61) and death (1.29, 0.84-1.98) were attenuated and no longer significant. Thus, assessing kidney function recovery and proteinuria status three months after AKI provides important prognostic information for long-term clinical outcomes.
- Published
- 2021
37. Publisher Correction: COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
- Author
-
Nadim, Mitra K, Forni, Lui G, Mehta, Ravindra L, Connor, Michael J, Liu, Kathleen D, Ostermann, Marlies, Rimmelé, Thomas, Zarbock, Alexander, Bell, Samira, Bihorac, Azra, Cantaluppi, Vincenzo, Hoste, Eric, Husain-Syed, Faeq, Germain, Michael J, Goldstein, Stuart L, Gupta, Shruti, Joannidis, Michael, Kashani, Kianoush, Koyner, Jay L, Legrand, Matthieu, Lumlertgul, Nuttha, Mohan, Sumit, Pannu, Neesh, Peng, Zhiyong, Perez-Fernandez, Xose L, Pickkers, Peter, Prowle, John, Reis, Thiago, Srisawat, Nattachai, Tolwani, Ashita, Vijayan, Anitha, Villa, Gianluca, Yang, Li, Ronco, Claudio, and Kellum, John A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Renal and urogenital ,Good Health and Well Being ,Urology & Nephrology ,Clinical sciences - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
38. Biological Mechanisms of COVID-19 Acute Respiratory Distress Syndrome.
- Author
-
Matthay, Michael A, Leligdowicz, Aleksandra, and Liu, Kathleen D
- Subjects
Humans ,Biological Products ,Immunity ,Patients ,Pandemics ,Respiratory Distress Syndrome ,COVID-19 ,SARS-CoV-2 ,Respiratory System ,Medical and Health Sciences - Published
- 2020
39. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
- Author
-
Nadim, Mitra K, Forni, Lui G, Mehta, Ravindra L, Connor, Michael J, Liu, Kathleen D, Ostermann, Marlies, Rimmelé, Thomas, Zarbock, Alexander, Bell, Samira, Bihorac, Azra, Cantaluppi, Vincenzo, Hoste, Eric, Husain-Syed, Faeq, Germain, Michael J, Goldstein, Stuart L, Gupta, Shruti, Joannidis, Michael, Kashani, Kianoush, Koyner, Jay L, Legrand, Matthieu, Lumlertgul, Nuttha, Mohan, Sumit, Pannu, Neesh, Peng, Zhiyong, Perez-Fernandez, Xose L, Pickkers, Peter, Prowle, John, Reis, Thiago, Srisawat, Nattachai, Tolwani, Ashita, Vijayan, Anitha, Villa, Gianluca, Yang, Li, Ronco, Claudio, and Kellum, John A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Prevention ,Kidney Disease ,Renal and urogenital ,Good Health and Well Being ,Acute Kidney Injury ,Anticoagulants ,COVID-19 ,Consensus ,Humans ,Renal Replacement Therapy ,Risk Factors ,SARS-CoV-2 ,Urology & Nephrology ,Clinical sciences - Abstract
Kidney involvement in patients with coronavirus disease 2019 (COVID-19) is common, and can range from the presence of proteinuria and haematuria to acute kidney injury (AKI) requiring renal replacement therapy (RRT; also known as kidney replacement therapy). COVID-19-associated AKI (COVID-19 AKI) is associated with high mortality and serves as an independent risk factor for all-cause in-hospital death in patients with COVID-19. The pathophysiology and mechanisms of AKI in patients with COVID-19 have not been fully elucidated and seem to be multifactorial, in keeping with the pathophysiology of AKI in other patients who are critically ill. Little is known about the prevention and management of COVID-19 AKI. The emergence of regional 'surges' in COVID-19 cases can limit hospital resources, including dialysis availability and supplies; thus, careful daily assessment of available resources is needed. In this Consensus Statement, the Acute Disease Quality Initiative provides recommendations for the diagnosis, prevention and management of COVID-19 AKI based on current literature. We also make recommendations for areas of future research, which are aimed at improving understanding of the underlying processes and improving outcomes for patients with COVID-19 AKI.
- Published
- 2020
40. Higher plasma cystatin C is associated with mortality after acute respiratory distress syndrome: findings from a Fluid and Catheter Treatment Trial (FACTT) substudy
- Author
-
Hendrickson, Carolyn M, Kwong, Yuenting D, Belzer, Annika G, Shlipak, Michael G, Matthay, Michael A, and Liu, Kathleen D
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lung ,Clinical Research ,Kidney Disease ,Rare Diseases ,Acute Respiratory Distress Syndrome ,Renal and urogenital ,Good Health and Well Being ,APACHE ,Adult ,Aged ,Biomarkers ,Cohort Studies ,Correlation of Data ,Cystatin C ,Female ,Humans ,Logistic Models ,Male ,Middle Aged ,Plasma ,Prospective Studies ,Respiratory Distress Syndrome ,Retrospective Studies ,Acute respiratory distress syndrome ,Acute kidney injury ,Medical and Health Sciences ,Emergency & Critical Care Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundCystatin C is a well-validated marker of glomerular filtration rate in chronic kidney disease. Higher plasma concentrations of cystatin C are associated with worse clinical outcomes in heterogenous populations of critically ill patients and may be superior to creatinine in identifying kidney injury in critically ill patients. We hypothesized that elevated levels of plasma cystatin C in patients with acute respiratory distress syndrome (ARDS) would be associated with mortality risk.MethodsIn a retrospective study, cystatin C was measured by nephelometry on plasma obtained at enrollment from 919 patients in the Fluid and Catheter Treatment Trial. Multivariable logistic regression was performed testing the association between quartiles of cystatin C and 60-day mortality. Analyses were stratified by acute kidney injury (AKI) status identified in the first 7 days after enrollment by Kidney Disease: Improving Global Outcomes (KDIGO) criteria.ResultsCystatin C was significantly higher among those patients who died compared to those who survived to 60 days [1.2 (0.9-1.9) mg/L vs. 0.8 (0.6-1.2) mg/L, p
- Published
- 2020
41. Genetic variation implicates plasma angiopoietin-2 in the development of acute kidney injury sub-phenotypes
- Author
-
Bhatraju, Pavan K, Cohen, Max, Nagao, Ryan J, Morrell, Eric D, Kosamo, Susanna, Chai, Xin-Ya, Nance, Robin, Dmyterko, Victoria, Delaney, Joseph, Christie, Jason D, Liu, Kathleen D, Mikacenic, Carmen, Gharib, Sina A, Liles, W Conrad, Zheng, Ying, Christiani, David C, Himmelfarb, Jonathan, and Wurfel, Mark M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Human Genome ,Genetics ,Kidney Disease ,2.1 Biological and endogenous factors ,Aetiology ,Renal and urogenital ,Acute Kidney Injury ,Adult ,Aged ,Angiopoietin-1 ,Angiopoietin-2 ,Critical Illness ,Endothelial Cells ,Female ,Genetic Predisposition to Disease ,Humans ,In Vitro Techniques ,Male ,Microvessels ,Middle Aged ,Polymorphism ,Single Nucleotide ,Receptors ,Tumor Necrosis Factor ,Type I ,White People ,Acute kidney injury ,Endothelium ,Urology & Nephrology ,Clinical sciences ,Health services and systems ,Nursing - Abstract
BackgroundWe previously identified two acute kidney injury (AKI) sub-phenotypes (AKI-SP1 and AKI-SP2) with different risk of poor clinical outcomes and response to vasopressor therapy. Plasma biomarkers of endothelial dysfunction (tumor necrosis factor receptor-1, angiopoietin-1 and 2) differentiated the AKI sub-phenotypes. However, it is unknown whether these biomarkers are simply markers or causal mediators in the development of AKI sub-phenotypes.MethodsWe tested for associations between single-nucleotide polymorphisms within the Angiopoietin-1, Angiopoietin-2, and Tumor Necrosis Factor Receptor 1A genes and AKI- SP2 in 421 critically ill subjects of European ancestry. Top performing single-nucleotide polymorphisms (FDR T, near ANGPT2 was associated with reduced risk of AKI-SP2 (odds ratio, 0.45; 95% CI, 0.31-0.66; adjusted FDR = 0.003) and decreased plasma angiopoietin-2 (p = 0.002). Causal inference analysis showed that for each minor allele (T) the risk of developing AKI-SP2 decreases by 16%. Plasma angiopoietin-2 mediated 41.5% of the rs2920656 related risk for AKI-SP2. Human kidney microvascular endothelial cells carrying the T allele of rs2920656 produced numerically lower levels of angiopoietin-2 although this was not statistically significant (p = 0.07). Finally, analyses demonstrated that angiopoietin-2 is minimally renally cleared in critically ill subjects.ConclusionGenetic mediation analysis provides supportive evidence that angiopoietin-2 plays a causal role in risk for AKI-SP2.
- Published
- 2020
42. Alternative Tobacco Product Use in Critically Ill Patients
- Author
-
Liu, Tom, Deiss, Thomas J, Lippi, Matthew W, Jauregui, Alejandra, Vessel, Kathryn, Ke, Serena, Belzer, Annika, Zhuo, Hanjing, Kangelaris, Kirsten N, Gomez, Antonio D, Matthay, Michael A, Liu, Kathleen D, and Calfee, Carolyn S
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Tobacco Smoke and Health ,Lung ,Tobacco ,Clinical Research ,Cancer ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Respiratory ,Good Health and Well Being ,Aged ,Critical Illness ,Female ,Humans ,Male ,Middle Aged ,Tobacco Products ,Tobacco Use ,United States ,non-cigarette tobacco products ,electronic nicotine delivery devices ,smoking-caused disease ,surveillance and monitoring ,alternative tobacco products ,critical illness ,survey research ,Toxicology - Abstract
Background: Alternative tobacco product (ATP) use has bee linked to critical illness, however, few studies have examined the use of these substances in critically ill populations. We sought to examine ATP use within critically ill patients and to define barriers in accurately assessing use within this population. Methods: We prospectively studied 533 consecutive patients from the Early Assessment of Renal and Lung Injury study, enrolled between 2013 and 2016 at a tertiary referral center and a safety-net hospital. ATP use information (electronic cigarettes, cigars, pipes, hookahs/waterpipes, and snus/chewing tobacco) was obtained from the patient or surrogate using a detailed survey. Reasons for non-completion of the survey were recorded, and differences between survey responders vs. non-responders, self- vs. surrogate responders, and ATP users vs. non-users were explored. Results: Overall, 80% (n = 425) of subjects (56% male) completed a tobacco product use survey. Of these, 12.2% (n = 52) reported current ATP use, while 5.6% reported using multiple ATP products. When restricted to subjects who were self-responders, 17% reported ATP use, while 10% reported current cigarette smoking alone. The mean age of ATP users was 57 ± 17 years. Those who did not complete a survey were sicker and more likely to have died during admission. Subjects who completed the survey as self-responders reported higher levels of ATP use than ones with surrogate responders (p < 0.0001). Conclusion: ATP use is common among critically ill patients despite them being generally older than traditional users. Survey self-responders were more likely than surrogate responders to report use. These findings highlight the importance of improving our current methods of surveillance of ATP use in older adults in the outpatient setting.
- Published
- 2020
43. Intraoperative Use of Albumin in Major Noncardiac Surgery: Incidence, Variability, and Association With Outcomes
- Author
-
Lazzareschi, Daniel V., Fong, Nicholas, Mavrothalassitis, Orestes, Whitlock, Elizabeth L., Chen, Catherine L., Chiu, Catherine, Adelmann, Dieter, Bokoch, Michael P., Chen, Lee-Lynn, Liu, Kathleen D., Pirracchio, Romain, Mathis, Michael R., and Legrand, Matthieu
- Published
- 2023
- Full Text
- View/download PDF
44. Association of patient weight status with plasma surfactant protein D, a biomarker of alveolar epithelial injury, in children with acute respiratory failure.
- Author
-
Ward, Shan L, Dahmer, Mary K, Weeks, Heidi M, Sapru, Anil, Quasney, Michael W, Curley, Martha AQ, Liu, Kathleen D, Matthay, Michael A, and Flori, Heidi R
- Subjects
Humans ,Respiratory Insufficiency ,Obesity ,Body Weight ,Pulmonary Surfactant-Associated Protein D ,Body Mass Index ,Adolescent ,Child ,Child ,Preschool ,Infant ,Female ,Male ,Biomarkers ,acute respiratory distress syndrome ,acute respiratory failure ,alveolar epithelial injury ,body mass index ,children ,mechanical ventilation ,obesity ,pediatric ,surfactant protein D ,Nutrition ,Clinical Research ,Lung ,Rare Diseases ,Acute Respiratory Distress Syndrome ,Pediatric ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Aetiology ,2.1 Biological and endogenous factors ,Respiratory ,Metabolic and endocrine ,Paediatrics and Reproductive Medicine ,Respiratory System - Abstract
Aims and objectivesAlveolar epithelial injury is a key determinant of acute respiratory failure (ARF) severity. Plasma surfactant protein D (SP-D), a biomarker of alveolar epithelial injury, is lower in obese adults with ARF compared to their lean peers. We aimed to determine if children with ARF have similar variance in plasma SP-D associated with their weight status on admission.MethodsPlasma SP-D was measured on days 0, 1, or 2 in children (1-18 years) with ARF enrolled in the genetic variation and biomarkers in children with acute lung injury and RESTORE studies. Weight classification (underweight, normal, overweight, and obese) was based on body mass index or weight-for-height z-scores. Associations between weight group and SP-D on each day were tested.ResultsInclusion criteria were met in 212 subjects, 24% were obese. There were no differences among weight groups in SP-D levels on days 0 and 1. However, on day 2, there was a statistically significant linear trend for lower SP-D levels as weight increased in both the univariate analysis (P = .02) and when adjusting for age, ethnicity, and diagnosis of pediatric acute respiratory distress syndrome (P = .05).ConclusionsObesity was associated with lower plasma SP-D levels on day 2 of ARF. This finding may be explained by altered ARF pathogenesis in obese individuals or a reduced incidence of ventilator-induced lung injury.
- Published
- 2020
45. Quality of Care for Acute Kidney Disease: Current Knowledge Gaps and Future Directions
- Author
-
Liu, Kathleen D, Forni, Lui G, Heung, Michael, Wu, Vin-Cent, Kellum, John A, Mehta, Ravindra L, Ronco, Claudio, Kashani, Kianoush, Rosner, Mitchell H, Haase, Michael, Koyner, Jay L, Investigators, Acute Disease Quality Initiative, and Mehta, Ravi
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Kidney Disease ,Clinical Research ,Patient Safety ,Renal and urogenital ,Good Health and Well Being ,acute kidney injury ,outcomes ,quality ,recovery ,Acute Disease Quality Initiative Investigators ,Biomedical and clinical sciences ,Health sciences - Abstract
Acute kidney injury (AKI) and acute kidney disease (AKD) are common complications in hospitalized patients and are associated with adverse outcomes. Although consensus guidelines have improved the care of patients with AKI and AKD, guidance regarding quality metrics in the care of patients after an episode of AKI or AKD is limited. For example, few patients receive follow-up laboratory testing of kidney function or post-AKI or AKD care through nephrology or other providers. Recently, the Acute Disease Quality Initiative developed a consensus statement regarding quality improvement goals for patients with AKI or AKD specifically highlighting efforts regarding quality and safety of care after hospital discharge after an episode of AKI or AKD. The goal is to use these measures to identify opportunities for improvement that will positively affect outcomes. We recommend that health care systems quantitate the proportion of patients who need and actually receive follow-up care after the index AKI or AKD hospitalization. The intensity and appropriateness of follow-up care should depend on patient characteristics, severity, duration, and course of AKI of AKD, and should evolve as evidence-based guidelines emerge. Quality indicators for discharged patients with dialysis requiring AKI or AKD should be distinct from end-stage renal disease measures. Besides, there should be specific quality indicators for those still requiring dialysis in the outpatient setting after AKI or AKD. Given the limited preexisting data guiding the care of patients after an episode of AKI or AKD, there is ample opportunity to establish quality measures and potentially improve patient care and outcomes. This review will provide specific evidence-based and expert opinion-based guidance for the care of patients with AKI or AKD after hospital discharge.
- Published
- 2020
46. Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
- Author
-
Files, D. Clark, Aggarwal, Neil, Albertson, Timothy, Auld, Sara, Beitler, Jeremy R., Berger, Paul, Burnham, Ellen L., Calfee, Carolyn S., Cobb, Nathan, Crippa, Alessio, Discacciati, Andrea, Eklund, Martin, Esserman, Laura, Friedman, Eliot, Gandotra, Sheetal, Khan, Kashif, Koff, Jonathan, Kumar, Santhi, Liu, Kathleen D., Martin, Thomas R., Matthay, Michael A., Meyer, Nuala J., Obermiller, Timothy, Robinson, Philip, Russell, Derek, Thomas, Karl, Wong, Se Fum, Wunderink, Richard G., Wurfel, Mark M., Yen, Albert, Youssef, Fady A., Darmanian, Anita, Dzierba, Amy L., Garcia, Ivan, Gosek, Katarzyna, Madahar, Purnema, Mittel, Aaron M., Muir, Justin, Rosen, Amanda, Schicchi, John, Serra, Alexis L., Wahab, Romina, Gibbs, Kevin W., Landreth, Leigha, LaRose, Mary, Parks, Lisa, Wynn, Adina, Ittner, Caroline A.G., Mangalmurti, Nilman S., Reilly, John P., Harris, Donna, Methukupally, Abhishek, Patel, Siddharth, Boerger, Lindsie, Kazianis, John, Higgins, Carrie, McKeehan, Jeff, Daniel, Brian, Fields, Scott, Hurst-Hopf, James, Jauregui, Alejandra, Brown Swigart, Lamorna, Blevins, Daniel, Nguyen, Catherine, Suarez, Alexis, Tanios, Maged A., Sarafian, Farjad, Shah, Usman, Adelman, Max, Creel-Bulos, Christina, Detelich, Joshua, Harris, Gavin, Nugent, Katherine, Spainhour, Christina, Yang, Philip, Haczku, Angela, Hardy, Erin, Harper, Richart, Morrissey, Brian, Sandrock, Christian, Budinger, G. R. Scott, Donnelly, Helen K., Singer, Benjamin D., Moskowitz, Ari, Coleman, Melissa, Levitt, Joseph, Lu, Ruixiao, Henderson, Paul, Asare, Adam, Dunn, Imogene, and Botello Barragan, Alejandro
- Published
- 2023
- Full Text
- View/download PDF
47. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
- Author
-
Ostermann, Marlies, Bellomo, Rinaldo, Burdmann, Emmanuel A, Doi, Kent, Endre, Zoltan H, Goldstein, Stuart L, Kane-Gill, Sandra L, Liu, Kathleen D, Prowle, John R, Shaw, Andrew D, Srisawat, Nattachai, Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C, Kellum, John A, Participants, Conference, Bagshaw, Sean M, Barreto, Erin F, Bihorac, Azra, Bobek, Ilona, Bouchard, Josée, Cerdá, Jorge, Chakravarthi, Rajasekara, De Rosa, Silvia, Engelman, Daniel T, Forni, Lui G, Hemmilä, Ulla K, Herzog, Charles A, Hoste, Eric A, Huen, Sarah C, Iseki, Kunitoshi, Joannidis, Michael, Kashani, Kianoush B, Koyner, Jay L, Kribben, Andreas, Lameire, Norbert, Levey, Andrew S, Macedo, Etienne, Małyszko, Jolanta, Meersch, Melanie, Mehta, Ravindra L, Mewburn, Irene, Mironova, Olga, Murray, Patrick T, Nadim, Mitra K, Pan, Jenny S, Pannu, Neesh, Peng, Zhiyong, Philips, Barbara, Ponce, Daniela, Ray, Patricio E, Ricci, Zaccaria, Rimmelé, Thomas, Ronco, Claudio, Siew, Edward D, Stevens, Paul E, Tolwani, Ashita J, Tonelli, Marcello, Vaara, Suvi T, van Dam, Marjel, Vijayan, Anitha, Wise, Michael, Wu, Vin-Cent, and Zarbock, Alexander
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Kidney Disease ,7.3 Management and decision making ,Management of diseases and conditions ,Renal and urogenital ,Acute Kidney Injury ,Humans ,acute kidney disease ,acute kidney injury ,fluid management ,nephrotoxicity ,renal replacement therapy ,risk stratification ,Conference Participants ,Urology & Nephrology ,Clinical sciences - Abstract
In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline on the classification and management of acute kidney injury (AKI). The guideline was derived from evidence available through February 2011. Since then, new evidence has emerged that has important implications for clinical practice in diagnosing and managing AKI. In April of 2019, KDIGO held a controversies conference entitled Acute Kidney Injury with the following goals: determine best practices and areas of uncertainty in treating AKI; review key relevant literature published since the 2012 KDIGO AKI guideline; address ongoing controversial issues; identify new topics or issues to be revisited for the next iteration of the KDIGO AKI guideline; and outline research needed to improve AKI management. Here, we present the findings of this conference and describe key areas that future guidelines may address.
- Published
- 2020
48. The attributable mortality of acute respiratory distress syndrome
- Author
-
Auriemma, Catherine L, Delucchi, Kevin, Liu, Kathleen D, and Calfee, Carolyn S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Acute Lung Injury ,Critical Illness ,Humans ,Respiratory Distress Syndrome ,Sepsis ,Public Health and Health Services ,Emergency & Critical Care Medicine ,Clinical sciences - Published
- 2020
49. Clinician Recognition of the Acute Respiratory Distress Syndrome: Risk Factors for Under-Recognition and Trends Over Time.
- Author
-
Schwede, Matthew, Lee, Robert Y, Zhuo, Hanjing, Kangelaris, Kirsten N, Jauregui, Alejandra, Vessel, Kathryn, Belzer, Annika, Deiss, Thomas, Matthay, Michael A, Liu, Kathleen D, and Calfee, Carolyn S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Acute Respiratory Distress Syndrome ,Lung ,Rare Diseases ,Management of diseases and conditions ,7.3 Management and decision making ,Respiratory ,Age Factors ,Delayed Diagnosis ,Diagnosis ,Differential ,Humans ,Intensive Care Units ,Racial Groups ,Respiration ,Artificial ,Respiratory Distress Syndrome ,Retrospective Studies ,Risk Factors ,San Francisco ,Severity of Illness Index ,Sex Factors ,Tertiary Care Centers ,Tidal Volume ,acute respiratory distress syndrome ,critical care ,diagnosis ,documentation ,electronic health record ,risk factors ,Nursing ,Public Health and Health Services ,Emergency & Critical Care Medicine ,Clinical sciences - Abstract
ObjectivesThe acute respiratory distress syndrome is common in critically ill patients. Recognition is crucial because acute respiratory distress syndrome is associated with a high mortality rate, and low tidal volume ventilation improves mortality. However, acute respiratory distress syndrome often goes unrecognized. Risk factors for under-recognition and trends over time have not been fully described.DesignRetrospective chart review of patients with acute respiratory distress syndrome from a prospective cohort study of critically ill patients. For each patient's ICU stay, we searched the chart for terms that indicated that acute respiratory distress syndrome was diagnosed, in the differential diagnosis, or treated with low tidal volume ventilation.SettingICUs at a tertiary hospital at the University of California, San Francisco between 2008 and 2016.PatientsCritically ill patients with acute respiratory distress syndrome.InterventionsNone.Measurements and main resultsAcute respiratory distress syndrome was recognized in 70% of patients, and recognition increased from 60% in 2008-2009 to 92% in 2016 (p = 0.004). Use of tidal volumes less than 6.5 mL/kg also increased (p < 0.001) from 20% to 92%. Increased acute respiratory distress syndrome severity (p = 0.01) and vasopressor use (p = 0.04) were associated with greater recognition. Clinician diagnosis of acute respiratory distress syndrome and inclusion of acute respiratory distress syndrome in the differential diagnosis were associated with tidal volumes less than 6.5 mL/kg (51% use of tidal volume ≤ 6.5 mL/kg if acute respiratory distress syndrome recognized vs 15% if not recognized; p = 0.002). Diagnosing acute respiratory distress syndrome was associated with lower tidal volume in multivariate analysis.ConclusionsAlthough acute respiratory distress syndrome recognition and low tidal volume ventilation use have increased over time, they remain less than universal. Clinician recognition of acute respiratory distress syndrome is associated with both systemic and respiratory severity of illness and is also associated with use of low tidal volume ventilation.
- Published
- 2020
50. Acute respiratory distress syndrome-attributable mortality in critically ill patients with sepsis
- Author
-
Auriemma, Catherine L, Zhuo, Hanjing, Delucchi, Kevin, Deiss, Thomas, Liu, Tom, Jauregui, Alejandra, Ke, Serena, Vessel, Kathryn, Lippi, Matthew, Seeley, Eric, Kangelaris, Kirsten N, Gomez, Antonio, Hendrickson, Carolyn, Liu, Kathleen D, Matthay, Michael A, Ware, Lorraine B, and Calfee, Carolyn S
- Subjects
Acute Respiratory Distress Syndrome ,Sepsis ,Clinical Research ,Infectious Diseases ,Patient Safety ,Rare Diseases ,Hematology ,Lung ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Respiratory ,Good Health and Well Being ,Berlin ,Critical Illness ,Hospital Mortality ,Humans ,Intensive Care Units ,Prospective Studies ,Respiratory Distress Syndrome ,Acute respiratory distress syndrome ,Acute lung injury ,Mortality ,Clinical Sciences ,Public Health and Health Services ,Emergency & Critical Care Medicine - Abstract
PurposePrevious studies assessing impact of acute respiratory distress syndrome (ARDS) on mortality have shown conflicting results. We sought to assess the independent association of ARDS with in-hospital mortality among intensive care unit (ICU) patients with sepsis.MethodsWe studied two prospective sepsis cohorts drawn from the Early Assessment of Renal and Lung Injury (EARLI; n = 474) and Validating Acute Lung Injury markers for Diagnosis (VALID; n = 337) cohorts. ARDS was defined by Berlin criteria. We used logistic regression to compare in-hospital mortality in patients with and without ARDS, controlling for baseline severity of illness. We also estimated attributable mortality, adjusted for illness severity by stratification.ResultsARDS occurred in 195 EARLI patients (41%) and 99 VALID patients (29%). ARDS was independently associated with risk of hospital death in multivariate analysis, even after controlling for severity of illness, as measured by APACHE II (odds ratio [OR] 1.65 (95% confidence interval [CI] 1.02, 2.67), p = 0.04 in EARLI; OR 2.12 (CI 1.16, 3.92), p = 0.02 in VALID). Patients with severe ARDS (P/F
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.